smiles,doi,title,publisher,year,access,compound_id,target_type,target_relation,target_value,target_units,bacteria,bacteria_unified,page_bacteria,origin_bacteria,section_bacteria,subsection_bacteria,page_target,origin_target,section_target,subsection_target,page_scaffold,origin_scaffold,page_residue,origin_residue,pdf
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',64,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',32,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',32,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',16,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',16,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',32,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',64,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',4,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',16,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',64,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',16,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',16,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',2,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',4,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',2,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',2,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',2,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',8,µg/mL,E. c. 25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',64,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',1,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',16,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,'=',256,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',2,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',1,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',2,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',128,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',128,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',1,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',8,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',32,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',8,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',4,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',4,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',8,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',128,µg/mL,E. C. 25922,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',128,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',32,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',16,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',128,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',16,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',32,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',32,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',32,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',16,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',128,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',64,µg/mL,E. c.,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',16,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',4,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,>,256,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',16,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',16,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',16,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',8,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',128,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',8,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',128,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',64,µg/mL,E. C.,Escherichia coli,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)n1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6a,MIC,'=',128,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6b,MIC,'=',128,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6c,MIC,'=',64,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6d,MIC,'=',64,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)c1C,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6e,MIC,'=',64,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6f,MIC,'=',256,µg mL-1,E.c.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35a,MIC,'=',"0,056",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35b,MIC,'=',"0,062",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccc([N+](=O)[O-])cc54)nn3)c2cc1C,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35c,MIC,'=',"0,058",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35d,MIC,'=',"0,03",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35e,MIC,'=',"0,056",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35f,MIC,'=',"0,052",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35g,MIC,'=',"0,026",µmol mL-1,E. coli,Escherichia coli,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
CSc1nnc(Cn2c(CSc3ccccc3)nc3ccccc32)n1-c1ccccc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,107a,MIC,'=',62,µg mL-1,E. coli,,24,table 9,,,24,table 9,,,25,scheme 27,25,scheme 27,antibiotics12071220
CCSc1nnc(Cn2c(CSc3ccccc3)nc3ccccc32)n1-c1ccccc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,107b,MIC,'=',72,µg mL-1,E. coli,,24,table 9,,,24,table 9,,,25,scheme 27,25,scheme 27,antibiotics12071220
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5a,MIC,'=',"0,07",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccccc54)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5b,MIC,'=',"0,065",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5c,MIC,'=',"0,067",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5d,MIC,'=',"0,062",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5e,MIC,'=',"0,058",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5f,MIC,'=',"0,057",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2cnc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5g,MIC,'=',"0,067",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4c5ccccc5CC4C)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5h,MIC,'=',"0,063",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2c3ccccc3CC2C)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5i,MIC,'=',"0,065",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2c3ccccc3CC2C)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5j,MIC,'=',"0,06",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5k,MIC,'=',"0,056",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5l,MIC,'=',"0,056",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5m,MIC,'=',"0,062",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccc([N+](=O)[O-])cc54)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5n,MIC,'=',"0,058",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5o,MIC,'=',"0,03",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5p,MIC,'=',"0,056",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5q,MIC,'=',"0,052",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5r,MIC,'=',"0,026",µmol/mL,E. coli,Escherichia coli,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
COc1cc(-c2nc3ccccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3a,MIC,'=',"0,27",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Cl)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3b,MIC,'=',"0,504",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Br)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3c,MIC,'=',"0,247",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(C)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3d,MIC,'=',"0,262",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1ccc2nc(-c3cc(OC)c(O)c4c[n+]5c(cc34)-c3cc4c(cc3CC5)OCO4)[nH]c2c1.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3e,MIC,'=',"0,254",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4a,MIC,'=',"0,51",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4b,MIC,'=',"0,483",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4c,MIC,'=',"0,471",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4d,MIC,'=',"0,029",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4e,MIC,'=',"0,437",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4f,MIC,'=',"0,417",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5a,MIC,'=',"0,015",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CCCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5b,MIC,'=',"0,112",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C=CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5c,MIC,'=',"0,249",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C#CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5d,MIC,'=',"0,25",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCO)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6a,MIC,'=',"0,494",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6b,MIC,'=',"0,47",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6c,MIC,'=',"0,436",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7a,MIC,'=',"0,22",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(F)cc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7b,MIC,'=',"0,107",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7c,MIC,'=',"0,428",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7d,MIC,'=',"0,202",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)c(Cl)c2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7e,MIC,'=',"0,202",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8a,MIC,'=',"0,219",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8b,MIC,'=',"0,426",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
CCN(CC)C(=O)Cn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9a,MIC,'=',"0,055",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N(C(C)C)C(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9b,MIC,'=',"0,416",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)OC(C)(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,10,MIC,'=',"0,218",mM,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8b,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8c,MIC,'=',"6,25",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8d,MIC,'=',50,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8g,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8h,MIC,'=',25,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8i,MIC,'=',25,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8l,MIC,'=',50,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8m,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8o,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8a,MIC,'=',"3,125",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8e,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8f,MIC,'=',25,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8j,MIC,'=',"6,25",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8k,MIC,'=',"3,125",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8n,MIC,'=',"3,125",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8p,MIC,'=',"12,5",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8q,MIC,'=',"6,25",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8r,MIC,'=',"3,125",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8s,MIC,'=',"3,125",µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8t,MIC,'=',50,µg mL-1,E. coli,Escherichia coli,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
O=C(c1ccncc1)N1N=C(c2nc3ccccc3[nH]2)CC1c1ccc(O)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,3g,MIC,'=',25,µg mL-1,E. coli,Escherichia coli,2,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,2,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,2,scheme 1,2,scheme 1,antibiotics10081002
Cc1ccc(C2CC(c3nc4ccccc4[nH]3)=NN2C(=O)c2ccncc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,3h,MIC,'=',25,µg mL-1,E. coli,Escherichia coli,2,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,2,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,2,scheme 1,2,scheme 1,antibiotics10081002
Cc1nn(-c2ccccc2)c2c1/C(=N/c1nc3ccccc3[nH]1)CO2,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,10,MIC,'=',50,µg mL-1,E. coli,Escherichia coli,3,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,3,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,3,scheme 3,,,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccc4)nc3-c3ccccc3)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28b,MIC,'=',312,µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
Oc1ccccc1-c1nn(-c2ccccc2)cc1-c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28c,MIC,'=',"187,5",µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccc4)nc3-c3ccccc3O)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28d,MIC,'=',250,µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
c1ccc(-c2nn(-c3ccccn3)cc2-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28e,MIC,'=',"187,5",µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccn4)nc3-c3ccccc3)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28f,MIC,'=',312,µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
Oc1ccccc1-c1nn(-c2ccccn2)cc1-c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28g,MIC,'=',"62,5",µg mL-1,E. coli,Escherichia coli,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccn4)nc3-c3ccccc3O)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28h,MIC,'=',125,µg mL-1,E. coli,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
ClN1N=C(c2c(-c3ccccc3)[nH]c3ccccc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31a,MIC,'=',8,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CN1N=C(c2c(-c3ccccc3)[nH]c3ccccc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31b,MIC,'=',32,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
c1ccc(-c2[nH]c3ccccc3c2C2=NNC(c3nc4ccccc4[nH]3)C2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31c,MIC,'=',128,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
ClN1N=C(c2c(-c3ccccc3)[nH]c3ccc(-c4ccccc4)cc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32a,MIC,'=',8,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CN1N=C(c2c(-c3ccccc3)[nH]c3ccc(-c4ccccc4)cc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32b,MIC,'=',32,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
c1ccc(-c2ccc3[nH]c(-c4ccccc4)c(C4=NNC(c5nc6ccccc6[nH]5)C4)c3c2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32c,MIC,'=',32,µg mL-1,Escherichia coli (MTCC-723),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CC1=NNC(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39a,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccccc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39b,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccc(Cl)cc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39c,MIC,'=',"7,81",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccc(F)cc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39d,MIC,'=',"7,81",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
COc1ccc(N2N=C(C)/C(=N/Nc3ccc(-c4nc5ccccc5[nH]4)cc3)C2=O)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39e,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2cccc(Cl)c2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39f,MIC,'=',"7,81",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2cccc(F)c2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39g,MIC,'=',"15,62",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(C(N)=S)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39h,MIC,'=',125,µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(C2CCC(N=C=O)C2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39i,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
Cc1ccc(-n2nc(C)c(-c3c(C#N)c(N)n4c(nc5cc(C)ccc54)c3C#N)c2Cc2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,61a,MIC,'=',200,µg mL-1,E. coli,,12,table 5,,,12,table 5,,,11,scheme 15,11,scheme 15,antibiotics10081002
Cc1ccc(Cc2c(-c3c(C#N)c(N)n4c(nc5cc(C)ccc54)c3C#N)c(C)nn2-c2ccc(C)cc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,61b,MIC,'=',250,µg mL-1,E. coli,,12,table 5,,,12,table 5,,,11,scheme 15,11,scheme 15,antibiotics10081002
Cc1ccc(-n2nc(C)c(-c3c(C#N)c(N)n4c(nc5cc(C)ccc54)c3C#N)c2Cc2ccc(Cl)cc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,61c,MIC,'=',"62,5",µg mL-1,E. coli,,12,table 5,,,12,table 5,,,11,scheme 15,11,scheme 15,antibiotics10081002
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,67,MIC,'=',"0,98",µg mL-1,E. coli,,12,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,12,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,13,scheme 17,,,antibiotics10081002
CCCCn1c(Cc2cc(C)[nH]n2)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,70,MIC,'=',50,µg mL-1,E. coli,,13,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,13,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,14,scheme 18,,,antibiotics10081002
Cn1c(-c2c(S(=O)(=O)c3ccccc3)nnc3c(-c4ccc(Cl)cc4)cnn23)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,74,MIC,'=',"16,5",µg mL-1,Escherichia coli anaerobic,,14,table 6,,,14,table 6,,,14,scheme 19,,,antibiotics10081002
c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88a,MIC,'=',"31,25",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
COc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88b,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Cc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88c,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Nc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88d,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Clc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88e,MIC,'=',"15,62",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Oc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88f,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Fc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88g,MIC,'=',"15,62",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
O=[N+]([O-])c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88h,MIC,'=',"15,62",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
FC(F)(F)c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88i,MIC,'=',"7,81",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
C=Cc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88j,MIC,'=',"31,25",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
COc1cc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)ccc1O,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88k,MIC,'=',"62,5",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
O=[N+]([O-])c1cccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88l,MIC,'=',"31,25",µg mL-1,Escherichia coli ATCC 25922,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
COc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccccc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6a,MIC,>,"163,2",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(C)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6b,MIC,'=',"157,4",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6c,MIC,>,"155,9",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Cl)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6d,MIC,'=',"149,9",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Br)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6e,MIC,'=',"33,9",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccccc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6f,MIC,'=',"163,2",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(C)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6g,MIC,'=',"9,8",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(F)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6h,MIC,'=',"38,9",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Cl)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6i,MIC,'=',"149,9",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Br)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6j,MIC,'=',"135,7",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccccc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6k,MIC,'=',"80,7",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Cc1ccc2nc(-c3sc(N4CCOCC4)nc3-c3ccc(Cl)cc3)[nH]c2c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6l,MIC,>,"155,7",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Fc1ccc2c(c1)[N]C(c1sc(N3CCOCC3)nc1-c1ccc(Cl)cc1)=N2,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6m,MIC,'=',"77,2",µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6n,MIC,>,"148,8",µM,E. coli,Escherichia coli,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(Br)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6o,MIC,>,135,µM,E. coli,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
CCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5a,MIC,'=',"9,375",µg/mL,E. coli,Escherichia coli,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
CCCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5b,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
N#CCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5c,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
FC(F)(F)c1cc(-c2ccccc2)nc(N2CCC(c3nc4ccccc4[nH]3)CC2)c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4a,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
FC(F)(F)c1cc(-c2ccccc2)nc(N2CCC(c3nc4ccc(Cl)cc4[nH]3)CC2)c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4b,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Fc1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4c,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4d,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
O=C(c1ccccc1)c1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4e,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4ccccc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4f,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4ccc(C(=O)c5ccccc5)cc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4g,MIC,>,150,µg/mL,E. coli,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4cc(Cl)ccc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4h,MIC,'=',75,µg/mL,E. coli,Escherichia coli,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
CNc1nnc(-c2ccc(-c3nc4cc(C)c(C)cc4[nH]3)cc2)s1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5a,MIC,'=',125,µg/mL,E. coli,Escherichia coli,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC(C)C)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5b,MIC,'=',"62,5",µg/mL,E. coli,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NCCCl)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5c,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(Nc5ccccc5Cl)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5d,MIC,'=',125,µg/mL,E. coli,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC5CCCCC5)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5e,MIC,'=',125,µg/mL,E. coli,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC(C)C)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5f,MIC,'=',"15,625",µg/mL,E. coli,Escherichia coli,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
CCCNc1nnc(-c2ccc(-c3nc4cc(C)c(C)cc4[nH]3)cc2)s1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5g,MIC,'=',"15,625",µg/mL,E. coli,Escherichia coli,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
COc1ccc(Nc2nnc(-c3ccc(-c4nc5cc(C)c(C)cc5[nH]4)cc3)s2)cc1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5h,MIC,'=',"31,25",µg/mL,E. coli,Escherichia coli,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
C[C@H]1COc2c(F)c(F)cc3c(=O)c(-c4nc5ccccc5n4C)cn1c23,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-1,MIC,'=',"0,625",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2c(F)c(F)c(F)c(F)c2-c2nc3ccccc3n2C)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-2,MIC,'=',"2,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(F)c(F)c2F)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-3,MIC,'=',5,µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(Cl)cc2Cl)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-4,MIC,'=',5,µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(Cl)c(Cl)c2Cl)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-5,MIC,'=',"2,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cnccn2)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-6,MIC,'=',5,µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
CCCc1nc2c(C)cc(-c3nc4ccccc4o3)cc2[nH]1,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-7,MIC,'=',"1,25",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cccc(F)c1Cn1cc(-c2nc3ccccc3o2)nn1,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-8,MIC,'=',"2,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1c(F)c(F)c(-c2nc3ccccc3o2)c(-c2nc3ccccc3o2)c1F,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-9,MIC,'=',"2,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cc(-c2nc3ccccc3o2)c(Cl)cc1Cl,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-10,MIC,'=',"0,156",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cc(-c2nc3ccccc3o2)c(Cl)c(Cl)c1Cl,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-11,MIC,'=',"1,25",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccccc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,13,MIC,>,"62,5",µg/mL,E. coli,,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccccc2C)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,14,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cccc(C)c2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,15,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,16,MIC,'=',"3,9",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccc(Cl)cc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,17,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccccc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,18,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccccc1C(=O)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,19,MIC,>,"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1cccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,20,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,21,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccc(Cl)cc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,22,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccccc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,23,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccccc1C(=O)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,24,MIC,>,"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1cccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,25,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,26,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccc(Cl)cc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,27,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cccnc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,28,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cncc(C)c2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,29,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccc(C)nc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,30,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,31,MIC,'=',"0,98",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1cncc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,32,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)cn1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,33,MIC,'=',"1,95",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,34,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1cncc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,35,MIC,'=',"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)cn1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,36,MIC,'=',"1,95",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccncc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,37,MIC,>,"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccncc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,38,MIC,>,"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
O=C(c1ccncc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,39,MIC,>,"62,5",µg/mL,E. coli,Escherichia coli,5,table 3,,,5,table 3,,,3,scheme 1,4,table 1,j.ejmech.2019.03.026
Cc1ccc2c(c1)n(CCCc1ccccc1)c(=N)n2CCCc1ccccc1,10.1016/j.bmc.2015.08.029,"Synthesis, electronic properties, antioxidant and antibacterial activity of some new benzimidazoles",Elsevier BV,2015,0,14,MIC,'=',"0,5",mg/mL,E. coli,Escherichia coli,3,table 1,,,3,table 1,,,3,scheme 1,3,scheme 1,j.bmc.2015.08.029
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',512,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',32,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',64,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3c,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',32,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',32,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',512,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',64,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4d,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',128,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',256,µg/mL,E. coli,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C=O)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,6a,MIC,'=',"5,52",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C=O)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,6b,MIC,'=',"6,37",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5ccccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7a,MIC,'=',"0,14",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5ccccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7h,MIC,'=',"0,32",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1ccc2c(c1)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(Br)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7b,MIC,'=',"4,5",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(Br)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7c,MIC,'=',"0,14",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Cl)ccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7f,MIC,'=',"0,14",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Br)ccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7g,MIC,'=',"4,03",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(F)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7k,MIC,'=',"0,31",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(F)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7j,MIC,'=',"0,61",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Br)ccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7n,MIC,'=',"4,47",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Cl)ccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7m,MIC,'=',"4,75",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5cc(F)ccc5[nH]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7d,MIC,'=',"0,56",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5ccc(C(F)(F)F)cc5[nH]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7e,MIC,'=',"1,03",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1ccc2[nH]c(-c3cc(Cn4cc(Cn5c(=O)cc(C)c6cc(F)ccc65)nn4)ccc3O)nc2c1,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7i,MIC,'=',"2,53",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5ccc(C(F)(F)F)cc5[nH]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7l,MIC,'=',"0,14",µmol/mL,E. coli (CIP 53154),Escherichia coli,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
O=C(O)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3a,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCN(CC)c1ccc(C=NNC(=O)c2ccc(-c3nc4ccc(Cl)cc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3b,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CC(C)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3c,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CSc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3d,MIC,'=',128,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(C(F)(F)F)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3e,MIC,'=',128,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(-c2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3f,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCOc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3g,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(OCc2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3h,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
N#Cc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3i,MIC,'=',128,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccccc1C(=O)O)c1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3j,MIC,'=',256,µg/mL,E. coli ATCC 25922,Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',16,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3c,MIC,'=',8,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',128,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',512,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4d,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',256,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',16,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',16,µg/mL,E. coli ATCC25922,Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6a,MIC,'=',"2 ± 0,23",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6b,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13a,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13b,MIC,'=',"16 ± 1,73",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13c,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13d,MIC,'=',"16 ± 1,73",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13e,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13f,MIC,'=',"0,125 ± 0,01",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13g,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13h,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13i,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13j,MIC,'=',"4 ± 0,58",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4CC)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14a,MIC,'=',"4 ± 0,58",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14b,MIC,'=',"32 ± 3,46",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14c,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14d,MIC,'=',"4 ± 0,58",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14e,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14f,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14g,MIC,'=',"256 ± 137,29",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14h,MIC,'=',"256 ± 137,29",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14i,MIC,'=',"2 ± 0,23",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14j,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14k,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14l,MIC,'=',"16 ± 1,73",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14m,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14n,MIC,'=',"128 ± 68,65",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14o,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14p,MIC,'=',"128 ± 68,65",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15a,MIC,'=',"2 ± 0,23",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15b,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15c,MIC,'=',"512 ± 49,65",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15d,MIC,'=',"128 ± 68,65",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15e,MIC,'=',"32 ± 3,46",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15f,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15g,MIC,'=',"16 ± 1,73",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15h,MIC,'=',"2 ± 0,23",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15i,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15j,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15k,MIC,'=',"256 ± 137,29",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15l,MIC,'=',"32 ± 3,46",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15m,MIC,'=',"0,125 ± 0,01",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15n,MIC,'=',"16 ± 1,73",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CCc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16a,MIC,'=',"32 ± 3,46",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CCc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16b,MIC,'=',"4 ± 0,58",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CNc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17a,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CNc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17b,MIC,'=',"1 ± 0,12",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
CCn1cc(C(=O)OC)c(=O)c2cc(F)c(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18a,MIC,'=',"32 ± 3,46",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
COC(=O)c1cn(C2CC2)c2cc(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18b,MIC,'=',"8 ± 1,15",µg/mL,E. coli DH52,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
O=C(Cn1c[n+](CC(=O)c2ccc(-c3ccccc3)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,11h,MIC,'=',"0,004",µg/mL,E. coli Escherichia coli ATCC 25922,Escherichia coli,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(CCn1c[n+](CC(=O)c2ccc(-c3ccccc3)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,12h,MIC,'=',"0,004",µg/mL,E. coli Escherichia coli ATCC 25922,Escherichia coli,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(Cn1c[n+](CC(=O)c2ccc(F)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,11f,MIC,'=',"0,009",µg/mL,E. coli Escherichia coli ATCC 25922,Escherichia coli,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(Cn1c[n+](CC(=O)c2ccc(Br)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,7h,MIC,'=',"0,001",µg/mL,E. coli Escherichia coli ATCC 25922,Escherichia coli,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(O)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3a,MIC,'=',256,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCN(CC)c1ccc(C=NNC(=O)c2ccc(-c3nc4ccc(Cl)cc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3b,MIC,'=',128,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CC(C)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3c,MIC,'=',128,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CSc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3d,MIC,'=',128,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(C(F)(F)F)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3e,MIC,'=',256,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(-c2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3f,MIC,'=',256,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCOc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3g,MIC,'=',256,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(OCc2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3h,MIC,'=',128,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),Escherichia coli,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
N#Cc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3i,MIC,'=',128,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccccc1C(=O)O)c1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3j,MIC,'=',256,µg/mL,E. coli isolate (contains broad spectrum β-lactamase enzyme - GSBL-),,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6a,MIC,'=',"8 ± 1,15",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6b,MIC,'=',"2 ± 0,23",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13a,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13b,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13c,MIC,'=',"2 ± 0,23",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13e,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13f,MIC,'=',"0,5 ± 0,05",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13g,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13i,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13j,MIC,'=',"8 ± 1,15",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4CC)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14a,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14b,MIC,'=',"128 ± 68,65",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14c,MIC,'=',"128 ± 68,65",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14d,MIC,'=',"64 ± 6,35",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14e,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14f,MIC,'=',"32 ± 3,46",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14g,MIC,'=',"512 ± 49,65",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14i,MIC,'=',"128 ± 68,65",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14j,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14k,MIC,'=',"128 ± 68,65",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14l,MIC,'=',"64 ± 6,35",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14m,MIC,'=',"2 ± 0,23",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14o,MIC,'=',"16 ± 1,73",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15a,MIC,'=',"16 ± 1,73",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15b,MIC,'=',"64 ± 6,35",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15f,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15g,MIC,'=',"8 ± 1,15",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15h,MIC,'=',"16 ± 1,73",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15i,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15j,MIC,'=',"2 ± 0,23",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15l,MIC,'=',"16 ± 1,73",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15m,MIC,'=',"1 ± 0,12",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15n,MIC,'=',"8 ± 1,15",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CCc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16b,MIC,'=',"2 ± 0,23",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CNc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17a,MIC,'=',"16 ± 1,73",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CNc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17b,MIC,'=',"4 ± 0,58",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
CCn1cc(C(=O)OC)c(=O)c2cc(F)c(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18a,MIC,'=',"64 ± 6,35",µg/mL,E. coli JM109,Escherichia coli,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
C/C(=N\NC(N)=S)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7a,MIC,'=',25,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NCc1ccccc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7b,MIC,'=',100,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC(C)(C)C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7c,MIC,'=',250,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC1CCCCC1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7d,MIC,'=',100,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC(C)C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7e,MIC,'=',"62,5",mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
COc1ccccc1NC(=S)N/N=C(\C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7f,MIC,'=',25,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(Cl)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7g,MIC,'=',500,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(F)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7h,MIC,'=',"62,5",mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
COc1ccc(NC(=S)N/N=C(\C)c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7i,MIC,'=',200,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccccc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7j,MIC,'=',250,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
CCNC(=S)N/N=C(\C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7k,MIC,'=',250,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(Br)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7l,MIC,'=',"62,5",mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1cccc(Cl)c1Cl)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7m,MIC,'=',100,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NCc1ccccc1)c1nc2ccc(Br)cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7n,MIC,'=',100,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,10,table 1,,,jhet.4548
C/C(=N\NC(=S)NC1CCCCC1)c1nc2cc(Br)ccc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7o,MIC,'=',25,mg/mL,E. coli MTCC 443,Escherichia coli,11,table 2,,,11,table 2,,,10,table 1,,,jhet.4548
C/C=N/NS(=O)(=O)Cc1ccc(N/N=C(\C#N)C2=Nc3ccccc3[N]2)cc1,10.1002/jccs.202000418J,Synthesis and in vivo evaluation of novel benzimidazole-sulfonamide hybrids and Lucilia cuprina maggots' excretion/secretion topical gels for wound healing,Wiley,2021,0,6b,MIC,'=',"9,07 ± 0,21",µg/mL,E. coli (RCMB010052),Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,jccs.202000418J
N#CC(=NNc1ccc(CS(=O)(=O)Nc2ncccn2)cc1)C1=Nc2ccccc2[N]1,10.1002/jccs.202000418J,Synthesis and in vivo evaluation of novel benzimidazole-sulfonamide hybrids and Lucilia cuprina maggots' excretion/secretion topical gels for wound healing,Wiley,2021,0,6d,MIC,'=',"13,93 ± 0,4",µg/mL,E. coli (RCMB010052),Escherichia coli,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,jccs.202000418J
Cc1cccc(Cn2c(C)nc3ccccc32)c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,53,MIC,'=',"0,5",µg/Ml,E. coli,Escherichia coli,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
Cc1cccc(Cn2cnc3cc(C)c(C)cc32)c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,54,MIC,>,256,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
N#CC(Nc1ccc(F)cc1)c1ccc(OCc2nc3ccccc3[nH]2)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,64,MIC,'=',"7,8",µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
O=C(c1ccc(Cl)cc1)c1cc2cc(Cc3ccc(O)c(-c4nc5ccc(Br)nc5[nH]4)c3)ccc2o1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,65,MIC,'=',120,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
O=C(c1ccc(Cl)cc1)c1cc2cc(Cc3ccc(O)c(-c4nc5ccc(F)cc5[nH]4)c3)ccc2o1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,66,MIC,'=',25,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
CC(=O)Nc1ccc(S(=O)(=O)Cc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,67,MIC,'=',32,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CC(=O)Nc1ccc(S(=O)(=O)Cc2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,68,MIC,'=',8,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=[N+]([O-])c1ccc2[nH]c(CNc3c([N+](=O)[O-])ccc4ncccc34)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,70,MIC,'=',"1,96",µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CCOC(=O)c1cn(Cc2nc3ccccc3n2Cc2ccccc2F)c2cc(Cl)c(F)cc2c1=O,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,72,MIC,'=',4,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CCCCCCn1c(COc2c3c(cc4c2OCc2cc5c(cc2-4)OCO5)CC[N+]([O-])=C3)nc2ccccc21.[Cl-],10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,73,MIC,'=',"3,12",µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Cl)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,74,MIC,'=',64,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
NNC(=O)c1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,75,MIC,>,32,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=C(N/N=C\c1ccccc1)c1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,76,MIC,>,32,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=C(N/N=C\c1ccc(Cl)cc1)c1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,77,MIC,>,32,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=C(N/N=C\c1ccc(Cl)cc1Cl)c1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,78,MIC,>,32,µg/Ml,E. coli,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
Cc1cccc(Cn2c(C)nc3ccccc32)c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,53,MIC,'=',8,µg/mL,S. aureus,Escherichia coli,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
Cc1cccc(Cn2cnc3cc(C)c(C)cc32)c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,54,MIC,'=',32,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
N#CC(Nc1ccc(F)cc1)c1ccc(OCc2nc3ccccc3[nH]2)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,64,MIC,'=',"3,9",µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
O=C(c1ccc(Cl)cc1)c1cc2cc(Cc3ccc(O)c(-c4nc5ccc(Br)nc5[nH]4)c3)ccc2o1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,65,MIC,'=',50,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
O=C(c1ccc(Cl)cc1)c1cc2cc(Cc3ccc(O)c(-c4nc5ccc(F)cc5[nH]4)c3)ccc2o1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,66,MIC,'=',50,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 6,,,0929867329666220407094430
CC(=O)Nc1ccc(S(=O)(=O)Cc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,67,MIC,'=',4,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CC(=O)Nc1ccc(S(=O)(=O)Cc2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,68,MIC,'=',64,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=[N+]([O-])c1ccc2[nH]c(CNc3c([N+](=O)[O-])ccc4ncccc34)nc2c1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,70,MIC,'=',"0,524",µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CCOC(=O)c1cn(Cc2nc3ccccc3n2Cc2ccccc2F)c2cc(Cl)c(F)cc2c1=O,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,72,MIC,'=',"3,91",µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
CCCCCCn1c(COc2c3c(cc4c2OCc2cc5c(cc2-4)OCO5)CC[N+]([O-])=C3)nc2ccccc21.[Cl-],10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,73,MIC,'=',"0,684",µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Cl)cc1,10.2174/0929867329666220407094430,Azole Derivatives: Recent Advances as Potent Antibacterial and Antifungal Agents,Bentham Science Publishers Ltd.,2023,0,74,MIC,'=',4,µg/mL,S. aureus,,13,table 3,,,13,table 3,,,11,figure 7,,,0929867329666220407094430
c1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4a,MIC,'=',50,µg/mL,E. coli,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
Clc1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4b,MIC,'=',"6,25",µg/mL,E. coli,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
Clc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4c,MIC,'=',"6,25",µg/mL,E. coli,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
Cc1cccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)c1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4d,MIC,'=',25,µg/mL,E. coli,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
Cc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4e,MIC,'=',25,µg/mL,E. coli,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
COc1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4f,MIC,'=',50,µg/mL,E. coli,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
COc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4g,MIC,'=',25,µg/mL,E. coli,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
O=[N+]([O-])c1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4h,MIC,'=',"3,125",µg/mL,E. coli,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
FC(F)(F)c1cccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)c1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4i,MIC,'=',50,µg/mL,E. coli,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
c1ccc(Cn2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4j,MIC,'=',25,µg/mL,E. coli,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
c1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4a,MIC,'=',25,µg/mL,S. aureus,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
Clc1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4b,MIC,'=',"6,25",µg/mL,S. aureus,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
Clc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4c,MIC,'=',"3,125",µg/mL,S. aureus,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
Cc1cccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)c1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4d,MIC,'=',25,µg/mL,S. aureus,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
Cc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4e,MIC,'=',50,µg/mL,S. aureus,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
COc1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4f,MIC,'=',50,µg/mL,S. aureus,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
COc1ccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4g,MIC,'=',"12,5",µg/mL,S. aureus,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
O=[N+]([O-])c1ccccc1-n1cc(Cn2cc(-c3nc4ccccc4[nH]3)c3ccccc32)nn1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4h,MIC,'=',"3,125",µg/mL,S. aureus,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
FC(F)(F)c1cccc(-n2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)c1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4i,MIC,'=',25,µg/mL,S. aureus,,4,table 5,,,4,table 5,,,3,scheme 1,,,s11030-018-9828-1
c1ccc(Cn2cc(Cn3cc(-c4nc5ccccc5[nH]4)c4ccccc43)nn2)cc1,10.1007/s11030-018-9828-1,"Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1,2,3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities",Springer Science and Business Media LLC,2018,0,4j,MIC,'=',"12,5",µg/mL,S. aureus,Escherichia coli,4,table 5,,,4,table 5,,,3,scheme 1,3,scheme 1,s11030-018-9828-1
Fc1ccc(-c2cc(-c3nc4ncccc4[nH]3)c3cc(Cl)ccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLV,MIC,'=',"6,25",µg/mL,E.coli,Escherichia coli,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)c3cc(Cl)ccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVI,MIC,'=',"6,25",µg/mL,E.coli,Escherichia coli,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4ncccc4[nH]3)c3ccccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVII,MIC,'=',"6,25",µg/mL,E.coli,Escherichia coli,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)c3ccccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVIII,MIC,'=',"6,25",µg/mL,E.coli,Escherichia coli,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
CC(=O)Nc1ccc(OCC(=O)N2N=C(c3nc4ccccc4[nH]3)CC2c2cccc(F)c2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,3,MIC,'=',"12,5",µg/mL,E.coli,,2,text,Reported Antibacterial Activity of Some Benzimidazole Derivatives,,2,text,Reported Antibacterial Activity of Some Benzimidazole Derivatives,,3,figure 3,,,RJC.2023.1638382
CC1=NN(c2ccc(Cl)cc2)C(=O)C1=NNc1ccc(-c2ccc(C3=Nc4ccccc4[N]3)cc2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,34,MIC,'=',"7,81",µg/mL,E.coli,Escherichia coli,7,text,Agents,,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,figure 11,,,RJC.2023.1638382
CC1=NN(c2cccc(Cl)c2)C(=O)/C1=N/Nc1ccc(-c2ccc(C3=Nc4ccccc4[N]3)cc2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,35,MIC,'=',"7,81",µg/mL,E.coli,Escherichia coli,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,figure 11,,,RJC.2023.1638382
CN(C)c1ccc(/C=C/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,1,pMIC,'=',"0,73",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
Oc1ccc2ccccc2c1C=Nc1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,2,pMIC,'=',"1,64",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,3,pMIC,'=',"1,35",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
Oc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,4,pMIC,'=',"0,82",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=[N+]([O-])c1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,5,pMIC,'=',"1,67",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,6,pMIC,'=',"1,67",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=[N+]([O-])c1cccc(/C=N/c2nc3ccccc3[nH]2)c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,7,pMIC,'=',"1,37",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
C/C=N/c1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,8,pMIC,'=',"1,59",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,9,pMIC,'=',"1,4",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=CCCC/C=N/c1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,10,pMIC,'=',"1,16",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3[nH]2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,11,pMIC,'=',1,µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
C/C=N/c1nc2ccccc2n1C(C)=O,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,12,pMIC,'=',"2,4",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,13,pMIC,'=',"1,75",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=CCCC/C=N/c1nc2ccccc2n1C(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,14,pMIC,'=',"2,3",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
CC(=O)n1c(/N=C/CCCC=O)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,15,pMIC,'=',"2,29",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=C(c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1)n1c(/N=C/c2ccc(O)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,16,pMIC,'=',"1,76",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)c(OC)c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,17,pMIC,'=',"1,46",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,18,pMIC,'=',"1,43",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3n2C(=O)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,19,pMIC,'=',"1,69",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2cc(OC)c(OC)c(OC)c2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,20,pMIC,'=',"1,66",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2ccc(-c3ccccn3)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,21,pMIC,'=',"1,45",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=C/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,22,pMIC,'=',"1,76",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,23,pMIC,'=',"1,78",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2c(O)ccc3ccccc23)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,24,pMIC,'=',"1,46",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,25,pMIC,'=',"1,78",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1ccc2ccccc2c1)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,26,pMIC,'=',"1,47",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,27,pMIC,'=',"1,76",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,28,pMIC,'=',"1,69",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2ccc(N(C)C)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,29,pMIC,'=',"1,67",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,30,pMIC,'=',"1,48",µM,EC,Escherichia coli,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4f,MIC,'=',256,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4c,MIC,'=',64,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4d,MIC,'=',64,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4b,MIC,'=',128,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)n1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4a,MIC,'=',128,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)c1C,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4e,MIC,'=',64,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5n4Cc4cn(-c5ccc(S(=O)(=O)Nc6nc(C)cc(C)n6)cc5)nn4)nn3)cc2)n1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6a,MIC,'=',64,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5ncccn5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6b,MIC,'=',64,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5ccccn5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6c,MIC,'=',32,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5nccs5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6d,MIC,'=',32,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5n4Cc4cn(-c5ccc(S(=O)(=O)Nc6onc(C)c6C)cc5)nn4)nn3)cc2)c1C,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6e,MIC,'=',32,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)NC(=N)N)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6f,MIC,'=',128,µg/mL,Ec,Escherichia coli,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
COc1ccc(-c2nc3sc(-c4ccc(C)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5c,MIC,'=',"04 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5d,MIC,'=',"05 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5f,MIC,'=',"04 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccccc4)nn3c2-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5h,MIC,'=',"04 ± 0,4",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccccc5[nH]4)c(-c4ccc(F)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5i,MIC,'=',"13 ± 0,5",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccc([N+](=O)[O-])cc5[nH]4)c(-c4ccc(F)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5j,MIC,'=',"04 ± 0,5",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5k,MIC,'=',"03 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Fc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5l,MIC,'=',"05 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(F)cc4)nn3c2-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5n,MIC,'=',"05 ± 0,3",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(F)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5o,MIC,'=',"05 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccccc5[nH]4)c(-c4ccc(Cl)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5p,MIC,'=',"04 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5cc(Cl)ccc5[nH]4)c(-c4ccc(Cl)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5r,MIC,'=',"04 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccccc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5u,MIC,'=',"04 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc([N+](=O)[O-])cc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5v,MIC,'=',"04 ± 0,3",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc(Cl)cc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5w,MIC,'=',"11 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccccc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5x,MIC,'=',"04 ± 0,2",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc([N+](=O)[O-])cc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5y,MIC,'=',"06 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc(Cl)cc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5z,MIC,'=',"04 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(C)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5aa,MIC,'=',"05 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(C)nn3c2-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5ac,MIC,'=',"08 ± 0,1",µg/mL,Escherichia coli,Escherichia coli,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
CC(=Nn1c(N=Cc2cccc(Cl)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5h,MIC,'=',50,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2Cl)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5g,MIC,'=',100,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(Cl)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5i,MIC,'=',100,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(Br)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5q,MIC,'=',25,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(Br)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5r,MIC,'=',50,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5a,MIC,'=',500,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2O)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5b,MIC,'=',500,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(O)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5c,MIC,'=',500,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(O)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5d,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(F)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5e,MIC,'=',100,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(F)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5f,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2C)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5j,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(C)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5k,MIC,'=',100,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(C)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5l,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
COc1cccc(C=Nc2c(C#N)c(-c3ccc([N+](=O)[O-])cc3)c(C#N)c(=O)n2N=C(C)c2nc3ccccc3[nH]2)c1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5m,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
COc1ccc(C=Nc2c(C#N)c(-c3ccc([N+](=O)[O-])cc3)c(C#N)c(=O)n2N=C(C)c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5n,MIC,'=',500,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc([N+](=O)[O-])c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5o,MIC,'=',250,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
C/C(=N\n1c(/N=C/c2ccc([N+](=O)[O-])cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5p,MIC,'=',1000,µg/mL,Escherichia coli (MTCC-443),Escherichia coli,4,table 1 (caption),,,4,table 1 (caption),,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
Clc1ccc(-c2nc3ccccc3[nH]2)c(Cl)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1c,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1d,MIC,'=',32,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1cccc(Cl)c1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1e,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1i,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1ccc(Br)cc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1k,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1l,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1m,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1n,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1o,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1q,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CN(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1r,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2c(-c3nc4ccccc4[nH]3)c3ccccc3cc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1s,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1cncc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1v,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2[nH]c(-c3ccncc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1w,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2a,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2b,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2c,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)c(Cl)c3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2d,MIC,'=',32,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3c(F)cccc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2e,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2f,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1cc(-c2nc3ccc(C)cc3[nH]2)ccc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2h,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc(F)cc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2i,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3O)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2j,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3cc(Br)ccc3O)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2k,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3cccc(O)c3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2l,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2m,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccc(C)cc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2n,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2o,MIC,'=',32,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3cccc([N+](=O)[O-])c3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2p,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2q,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccc(N(C)C)cc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2r,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3c4ccccc4cc4ccccc34)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2s,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3cccnc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2v,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccncc3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2w,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3a,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)c(Cl)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3b,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(OC)c(OC)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3c,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3d,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3e,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3f,MIC,'=',646,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3g,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CCOc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3h,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1cccc(-c2nc3ccccc3n2Cc2ccccc2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3j,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3k,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2Cl)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3l,MIC,'=',16,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4a,MIC,'=',256,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4b,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4c,MIC,'=',16,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)c(Cl)c3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4d,MIC,'=',32,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(F)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4e,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4f,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4g,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4h,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4i,MIC,'=',32,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccc(Cl)cc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4j,MIC,'=',64,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccco3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4k,MIC,'=',128,µg mL-1,Escherichia coli ATCC 25922,Escherichia coli,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1cc(C)n(C(=O)Cn2c(C3CC(=O)N(c4ccc(F)cc4)C3)nc3ccccc32)n1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,94b,MIC,'=',250,µg mL-1,Escherichia coli ATCC 8739,Escherichia coli,18,text,2.2. Benzimidazoles Substituted in the Position “1” with Pyrazole Moiety,,18,text,,,19,scheme 26,19,scheme 26,antibiotics10081002
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Cl)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,12,MIC,'=',"3,12",µg ml-1,Escherichia coli MTCC 739,Escherichia coli,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,13,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Br)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,14,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(C(F)(F)F)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,15,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(Cl)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,16,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccccc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,17,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc([N+](=O)[O-])c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,18,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
Cc1cccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,19,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
COc1ccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,20,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1F,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,21,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cc(Cl)ccc1Cl,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,22,MIC,>,50,µg ml-1,Escherichia coli MTCC 739,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
CC(=Nn1c(N=Cc2cccc(Cl)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5h,MIC,>,50,µg/mL,Methicillin-resistant S. aureus (ATCC 43300),Staphylococcus aureus,4,table 2 (caption),,,4,table 2,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(Br)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5q,MIC,'=',"12,5",µg/mL,Methicillin-resistant S. aureus (ATCC 43300),Staphylococcus aureus,4,table 2 (caption),,,4,table 2,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(Br)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5r,MIC,'=',"6,25",µg/mL,Methicillin-resistant S. aureus (ATCC 43300),Staphylococcus aureus,4,table 2 (caption),,,4,table 2,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
Clc1cc2nc(Cl)n(C3CCCC3)c2cc1Cl,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,22,MIC,'=',"6,25",µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Clc1cc2nc(Br)n(C3CCCC3)c2cc1Cl,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,23,MIC,'=',"6,25",µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Nc1nc2cc(Cl)c(Cl)cc2n1C1CCCC1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,24,MIC,'=',"6,25",µg/mL,MRSA,,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Clc1ccc2c(c1)nc(-c1ccc(OCc3ccccc3)cc1)n2C1CCCC1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,25,MIC,'=',"6,25",µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Cc1nc2ccc(C(=O)Nc3cccc(-c4ccc(-n5c(C)nc6cc(C(=O)NCCN(C)C)ccc65)nc4)c3)cc2[nH]1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,26,MIC,'=',2,µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Cc1nc2ccc(C(=O)Nc3cccc(-c4ccc(-n5c(C)nc6cc(C(=O)NCCCN(C)C)ccc65)nc4)c3)cc2[nH]1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,27,MIC,'=',"0,5",µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Cc1nc2ccc(C(=O)Nc3cccc(-c4ccc(-n5c(C)nc6cc(C(=O)NCCCCN(C)C)ccc65)nc4)c3)cc2[nH]1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,28,MIC,'=',1,µg/mL,MRSA,Staphylococcus aureus,5,figure 7,,,5,figure 7,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
O=C(O)CC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,4,MIC,'=',"21,16",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,5,MIC,'=',"40,41",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,6,MIC,'=',"148,2",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,7,MIC,'=',"37,05",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,8,MIC,'=',"79,8",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,9,MIC,'=',"38,19",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,10,MIC,'=',"9,15",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3cc(C)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,11,MIC,'=',"32,175",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,12,MIC,'=',"59,3",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,13,MIC,'=',"75,8",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,14,MIC,'=',"36,36",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,15,MIC,'=',"69,8",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,16,MIC,'=',"134,47",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,17,MIC,'=',"33,61",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,18,MIC,'=',"18,33",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,19,MIC,'=',"16,96",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,20,MIC,'=',"44,12",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,21,MIC,'=',"32,69",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,22,MIC,'=',"32,6",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)CC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,23,MIC,'=',"76,84",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)CCC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,24,MIC,'=',"73,67",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)CCCC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,25,MIC,'=',"35,37",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3cc(OC)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,26,MIC,'=',"34,02",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)CCCCC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,27,MIC,'=',"34,08",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,28,MIC,'=',"42,18",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,29,MIC,'=',"10,07",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,30,MIC,'=',"38,54",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,31,MIC,'=',"36,94",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,32,MIC,'=',"9,23",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,33,MIC,'=',"46,88",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,34,MIC,'=',"37,6",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,35,MIC,'=',"9,102",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,36,MIC,'=',"17,32",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,37,MIC,'=',"69,49",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,38,MIC,'=',"4,15",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,39,MIC,'=',"46,98",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,40,MIC,'=',"16,98",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)COCC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,41,MIC,'=',"17,58",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2[nH]c(-c3ccc(NC(=O)CSCC(=O)O)cc3)nc2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,42,MIC,'=',"67,31",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,43,MIC,'=',"38,3",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,44,MIC,'=',"9,12",µM,MRSA,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1cc(-c2nc3ccccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3a,MIC,'=',"0,068",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Cl)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3b,MIC,'=',"0,031",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Br)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3c,MIC,'=',"0,247",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(C)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3d,MIC,'=',"0,033",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1ccc2nc(-c3cc(OC)c(O)c4c[n+]5c(cc34)-c3cc4c(cc3CC5)OCO4)[nH]c2c1.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3e,MIC,'=',"0,254",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4a,MIC,'=',"0,016",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4b,MIC,'=',"0,121",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4c,MIC,'=',"0,059",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4d,MIC,'=',"0,115",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4e,MIC,'=',"0,218",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4f,MIC,'=',"0,208",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5a,MIC,'=',"0,242",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CCCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5b,MIC,'=',"0,225",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C=CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5c,MIC,'=',"0,249",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C#CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5d,MIC,'=',"0,25",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCO)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6a,MIC,'=',"0,247",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6b,MIC,'=',"0,47",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6c,MIC,'=',"0,218",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7a,MIC,'=',"0,014",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(F)cc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7b,MIC,'=',"0,107",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7c,MIC,'=',"0,214",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7d,MIC,'=',"0,006",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)c(Cl)c2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7e,MIC,'=',"0,101",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8a,MIC,'=',"0,219",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8b,MIC,'=',"0,213",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
CCN(CC)C(=O)Cn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9c,MIC,'=',"0,218",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N(C(C)C)C(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9b,MIC,'=',"0,208",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)OC(C)(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,10,MIC,'=',"0,218",mM,MRSA N315,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',32,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',128,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',32,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',4,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',8,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',8,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant S. aureus N315",,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',128,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',128,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',128,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',4,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',16,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',16,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',64,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',4,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',64,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',8,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',128,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',16,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',4,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',16,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',4,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',4,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',8,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',32,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',64,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',64,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',64,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',16,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',16,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',32,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',32,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',8,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',32,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',32,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',128,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',8,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',4,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',8,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',1,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',2,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',4,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',2,µg/mL,S. aureus 25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1ccco1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5a,MIC,'=',64,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5b,MIC,'=',64,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,5c,MIC,'=',32,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6a,MIC,'=',16,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6b,MIC,'=',32,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6c,MIC,'=',128,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1cccs1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6d,MIC,'=',256,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6e,MIC,'=',4,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc([N+](=O)[O-])cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6f,MIC,'=',16,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3ccc(Cl)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6g,MIC,'=',16,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(C)c(C)cc32)NC(=O)NC1c1sccc1C,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,6h,MIC,'=',32,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(F)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9a,MIC,'=',8,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9b,MIC,'=',2,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(F)cc1F,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9c,MIC,'=',4,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(C(F)(F)F)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9d,MIC,'=',2,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1cccc(Cl)c1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9e,MIC,'=',2,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9f,MIC,'=',4,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCOC(=O)C1=C(Cn2cnc3cc(Br)ccc32)NC(=O)NC1c1ccc(Cl)cc1Cl,10.1002/cjoc.202200326,A New Discovery towards Novel Skeleton of <scp>Benzimidazole‐Conjugated</scp> Pyrimidinones as Unique Effective Antibacterial Agents,Wiley,2022,0,9g,MIC,'=',8,µg/mL,S. aureus 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,cjoc.202200326
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3с,MIC,'=',16,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',256,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',512,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',64,µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6a,MIC,'=',"4 ± 0,58",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6b,MIC,'=',"0,5 ± 0,05",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13a,MIC,'=',"1 ± 0,12",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13b,MIC,'=',"16 ± 1,73",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13c,MIC,'=',"1 ± 0,12",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13d,MIC,'=',"32 ± 3,46",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13e,MIC,'=',"8 ± 1,15",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13f,MIC,'=',"0,125 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13g,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13h,MIC,'=',"0,5 ± 0,05",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13i,MIC,'=',"4 ± 0,58",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13j,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4CC)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14a,MIC,'=',"8 ± 1,15",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14b,MIC,'=',"16 ± 1,73",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14c,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14d,MIC,'=',"32 ± 3,46",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14e,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14f,MIC,'=',"8 ± 1,15",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14g,MIC,'=',"256 ± 137,29",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14h,MIC,'=',"128 ± 68,65",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14i,MIC,'=',"128 ± 68,65",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14j,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14k,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14l,MIC,'=',"128 ± 68,65",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14m,MIC,'=',"0,125 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14n,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14o,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14p,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15a,MIC,'=',"0,125 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15b,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15c,MIC,'=',"256 ± 137,29",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15d,MIC,'=',"32 ± 3,46",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15e,MIC,'=',"16 ± 1,73",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15f,MIC,'=',"0,125 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15g,MIC,'=',"8 ± 1,15",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15h,MIC,'=',"4 ± 0,58",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15i,MIC,'=',"0,5 ± 0,05",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15j,MIC,'=',"0,25 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15k,MIC,'=',"8 ± 1,15",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15l,MIC,'=',"4 ± 0,58",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15m,MIC,'=',"0,125 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15n,MIC,'=',"2 ± 0,23",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CCc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16a,MIC,'=',"16 ± 1,73",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CCc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16b,MIC,'=',"4 ± 0,58",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CNc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17a,MIC,'=',"0,5 ± 0,05",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CNc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17b,MIC,'=',"0,25 ± 0,01",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
CCn1cc(C(=O)OC)c(=O)c2cc(F)c(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18a,MIC,'=',"128 ± 68,65",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
COC(=O)c1cn(C2CC2)c2cc(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18b,MIC,'=',"64 ± 6,35",µg/mL,"MRSA, Methicillin-Resistant Staphylococcus aureus N315",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',2,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',32,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',1,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,>,256,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',8,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',2,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',1,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',64,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',128,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',16,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',64,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',64,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',256,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',128,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',32,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',1,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',128,µg/mL,"MRSA, methicillin-resistant Staphylococcus aureus N315",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Clc1ccccc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1a,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1b,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)c(Cl)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1c,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1d,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1cccc(Cl)c1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1e,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1f,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1g,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1h,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1i,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1ccccc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1j,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1ccc(Br)cc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1k,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1l,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1m,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1n,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1o,MIC,'=',32,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
O=[N+]([O-])c1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1p,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1q,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CN(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1r,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2c(-c3nc4ccccc4[nH]3)c3ccccc3cc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1s,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2[nH]c(-c3ccc4c(c3)OCO4)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1t,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1cncc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1v,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2[nH]c(-c3ccncc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1w,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2a,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2b,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)cc3Cl)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2c,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)c(Cl)c3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2d,MIC,'=',32,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3c(F)cccc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2e,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2f,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1ccc(-c2nc3cc(C)ccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2g,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1cc(-c2nc3cc(C)ccc3[nH]2)ccc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2h,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(F)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2i,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3O)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2j,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cc(Br)ccc3O)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2k,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cccc(O)c3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2l,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2m,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccc(C)cc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2n,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2o,MIC,'=',32,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3cccc([N+](=O)[O-])c3)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2p,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2q,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(N(C)C)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2r,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3c4ccccc4cc4ccccc34)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2s,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc4c(c3)OCO4)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2t,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccco3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2u,MIC,'=',512,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cccnc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2v,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccncc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2w,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3a,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)c(Cl)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3b,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(OC)c(OC)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3c,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3d,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3e,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3f,MIC,'=',16,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3g,MIC,'=',8,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CCOc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3h,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1cccc(-c2nc3ccccc3n2Cc2ccccc2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3j,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3k,MIC,'=',4,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2Cl)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3l,MIC,'=',16,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4a,MIC,'=',32,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4b,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4c,MIC,'=',8,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)c(Cl)c3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4d,MIC,'=',32,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(F)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4e,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4f,MIC,'=',256,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4g,MIC,'=',16,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4h,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4i,MIC,'=',64,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccc(Cl)cc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4j,MIC,'=',8,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccco3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4k,MIC,'=',128,µg mL-1,"MRSA, Methicillin-resistant strains of Staphylococcus aureus ATCC 43300",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccccc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1a,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1b,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)c(Cl)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1c,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Clc1ccc(-c2nc3ccccc3[nH]2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1d,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1cccc(Cl)c1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1e,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1f,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1g,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1cc(-c2nc3ccccc3[nH]2)ccc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1h,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Fc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1i,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1ccc(Br)cc1-c1nc2ccccc2[nH]1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1k,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Oc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1l,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccccc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1m,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1n,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1o,MIC,'=',16,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1q,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CN(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1r,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2c(-c3nc4ccccc4[nH]3)c3ccccc3cc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1s,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2[nH]c(-c3ccc4c(c3)OCO4)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1t,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1cncc(-c2nc3ccccc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1v,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
c1ccc2[nH]c(-c3ccncc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,1w,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3Cl)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2a,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2b,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)cc3Cl)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2c,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(Cl)c(Cl)c3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2d,MIC,'=',16,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2f,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1ccc(-c2nc3cc(C)ccc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2g,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CCOc1cc(-c2nc3cc(C)ccc3[nH]2)ccc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2h,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(F)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2i,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2nc(-c3ccccc3O)[nH]c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2j,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cc(Br)ccc3O)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2k,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cccc(O)c3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2l,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1O,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2m,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
COc1cccc(-c2nc3ccc(C)cc3[nH]2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2n,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3[nH]2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2o,MIC,'=',16,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc([N+](=O)[O-])cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2q,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc(N(C)C)cc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2r,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3c4ccccc4cc4ccccc34)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2s,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccc4c(c3)OCO4)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2t,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccco3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2u,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3cccnc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2v,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
Cc1ccc2[nH]c(-c3ccncc3)nc2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,2w,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,7,table 3 (caption),,,6,table 3,,,3,scheme 1,4,table 1,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3a,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)c(Cl)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3b,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(OC)c(OC)c2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3c,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3d,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3e,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1Cl,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3f,MIC,'=',8,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1OC,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3g,MIC,'=',4,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CCOc1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3h,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
COc1cccc(-c2nc3ccccc3n2Cc2ccccc2)c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3j,MIC,'=',256,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
O=[N+]([O-])c1ccc(-c2nc3ccccc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3k,MIC,'=',4,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Clc1ccc(-c2nc3ccccc3n2Cc2ccccc2Cl)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,3l,MIC,'=',8,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc(Cl)cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4a,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
C=CCn1c(-c2ccc([N+](=O)[O-])cc2)nc2ccc(C)cc21,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4b,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4c,MIC,'=',4,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)c(Cl)c3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4d,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(F)cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4e,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CSc1ccc(-c2nc3ccc(C)cc3n2Cc2ccccc2)cc1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4f,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4g,MIC,'=',8,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4h,MIC,'=',64,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4i,MIC,'=',32,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccc([N+](=O)[O-])cc3)n(Cc3ccc(Cl)cc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4j,MIC,'=',8,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
Cc1ccc2nc(-c3ccco3)n(Cc3ccccc3)c2c1,10.1039/d2ra06667j,"N,2,6-Trisubstituted 1H-benzimidazole derivatives as a new scaffold of antimicrobial and anticancer agents: design, synthesis, in vitro evaluation, and in silico studies",Royal Society of Chemistry (RSC),2022,1,4k,MIC,'=',128,µg mL-1,"MSSA, Methicillin-susceptible strains of Staphylococcus aureus ATCC 29213",Staphylococcus aureus,8,table 4 (caption),,,8,table 4,,,3,scheme 1,5,table 2,d2ra06667j
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',8,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',4,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',"0,5",µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,'=',256,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',64,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',2,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',32,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',16,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',64,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',64,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',4,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',128,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',2,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',8,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',8,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',8,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',16,µg/mL,"S. A. 25923, Staphylococcus aureus ATCC 25923",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',32,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',16,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',"0,5",µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,'=',128,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',4,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',64,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',8,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',16,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',64,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',32,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',32,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',64,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',64,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',64,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',2,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',32,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',8,µg/mL,"S. A., 29213, Staphylococcus aureus ATCC 29213",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncccn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1a,MIC,'=',64,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1b,MIC,'=',4,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(N)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1c,MIC,'=',1,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nccc(C(F)(F)F)n4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1d,MIC,>,256,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(C)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1e,MIC,'=',4,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1f,MIC,'=',8,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(OC)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1g,MIC,'=',2,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(F)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1h,MIC,'=',4,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4ncc(Br)cn4)CC3)cc21,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1i,MIC,'=',8,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncccn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1j,MIC,'=',4,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1ccnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)n1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1k,MIC,'=',256,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nccc(C(F)(F)F)n4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1l,MIC,'=',128,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1m,MIC,'=',128,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
CCc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1n,MIC,'=',1,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
COc1cnc(N2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc1,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1o,MIC,'=',256,µg/mL,"S. A., Staphylococcus aureus",Staphylococcus aureus,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(F)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1p,MIC,'=',8,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4ncc(Br)cn4)CC3)c(F)cc2c1=O,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents,Elsevier BV,2022,0,1q,MIC,'=',16,µg/mL,"S. A., Staphylococcus aureus",,3,table 1,,,3,table 1,,,3,figure 2,3,figure 2,j.bmcl.2022.128885
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)n1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6a,MIC,'=',64,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6b,MIC,'=',128,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6c,MIC,'=',128,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6d,MIC,'=',128,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)c1C,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6e,MIC,'=',128,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,6f,MIC,'=',512,µg mL-1,S.a.,,5,table 1,,,5,table 1,,,5,scheme 2,5,scheme 2,antibiotics12071220
CC(=NNC(=O)Cn1cc(CSc2nc3ccccc3[nH]2)nn1)c1ccc(Br)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,3b,MIC,'=',18,µmol mL-1,S. aureus,Staphylococcus aureus,4,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.1. 2-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",4,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.1. 2-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",5,scheme 1,5,scheme 1,antibiotics12071220
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35a,MIC,'=',"0,028",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35b,MIC,'=',"0,031",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccc([N+](=O)[O-])cc54)nn3)c2cc1C,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35c,MIC,'=',"0,029",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35d,MIC,'=',"0,06",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35e,MIC,'=',"0,029",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35f,MIC,'=',"0,026",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
O=C(Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,35g,MIC,'=',"0,031",µmol mL-1,S. aureus,Staphylococcus aureus,10,table 3,,,10,table 3,,,10,scheme 8,10,scheme 8,antibiotics12071220
CN(C)c1ccc(/C=N/NC(=O)Cn2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,2k,MIC,'=',"12,5",µmol mL-1,S. aureus,,4,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.1. 2-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",4,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.1. 2-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",5,scheme 1,5,scheme 1,antibiotics12071220
CCOC(=O)Cn1cc(Cn2c(=O)n(Cc3ccccc3)c3ccccc32)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,37b,MIC,'=',"3,125",µgmL-1,S. aureus,,10,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.2. 1-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",10,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.2. 1-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",10,scheme 9,10,scheme 9,antibiotics12071220
O=c1n(Cc2ccccc2)c2ccccc2n1Cc1cn(-c2ccccc2)nn1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,37d,MIC,'=',"3,125",µgmL-1,S. aureus,,10,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.2. 1-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",10,text,"2. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,3-Triazoles","2.2. 1-Benzimidazole-R(Ar)-1,4-Disubstituted-1,2,3-Triazole Hybrids",10,scheme 9,10,scheme 9,antibiotics12071220
O=C1c2cccc3c(Sc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)ccc(c23)C(=O)N1CCCCn1c[n+](Cc2ccccc2Cl)cn1.[Cl-],10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,68g,MIC,'=',2,µg mL-1,S. aureus,,16,text,"3. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,4-Triazoles","3.1 2-Benzimidazole-R(Ar)-1-(1,2,4-Triazole)",16,text,"3. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,4-Triazoles","3.1 2-Benzimidazole-R(Ar)-1-(1,2,4-Triazole)",16,scheme 18,16,scheme 18,antibiotics12071220
CCCCCCC[n+]1cnn(CCCCN2C(=O)c3cccc4c(Sc5nc6ccccc6n5Cc5ccc(Cl)cc5Cl)ccc(c34)C2=O)c1.[Cl-],10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,69b,MIC,'=',2,µg mL-1,S. aureus,,16,text,"3. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,4-Triazoles","3.1 2-Benzimidazole-R(Ar)-1-(1,2,4-Triazole)",16,text,"3. Synthesis and Antimicrobial Activities of Benzimidazole-1,2,4-Triazoles","3.1 2-Benzimidazole-R(Ar)-1-(1,2,4-Triazole)",16,scheme 18,16,scheme 18,antibiotics12071220
Cc1nc2ccccc2n1-c1nnc(S)n1-c1ccc(O)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,88b,MIC,'=',8,µg mL-1,S. aureus,,21,table 6,,,21,table 6,,,21,scheme 22,21,scheme 22,antibiotics12071220
COc1ccc(-n2c(S)nnc2-n2c(C)nc3ccccc32)cc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,88c,MIC,'=',8,µg mL-1,S. aureus,,21,table 6,,,21,table 6,,,21,scheme 22,21,scheme 22,antibiotics12071220
Oc1nnc(-n2c(SCc3ccccc3)nc3ccccc32)[nH]1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,95,MIC,'=',18,800 µg mL-1,S. aureus,,23,table 8,,,23,table 8,,,22,scheme 24,,,antibiotics12071220
Oc1nnc(-n2c(SCc3ccccc3)nc3ccccc32)n1-c1ccccc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,96,MIC,'=',19,800 µg mL-1,S. aureus,,23,table 8,,,23,table 8,,,22,scheme 24,,,antibiotics12071220
Nn1c(O)nnc1-n1c(SCc2ccccc2)nc2ccccc21,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,97,MIC,'=',17,800 µg mL-1,S. aureus,,23,table 8,,,23,table 8,,,22,scheme 24,,,antibiotics12071220
CSc1nnc(Cn2c(CSc3ccccc3)nc3ccccc32)n1-c1ccccc1,10.3390/antibiotics12071220,Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review,MDPI AG,2023,1,107a,MIC,'=',105,µg mL-1,S. aureus,,24,table 9,,,24,table 9,,,25,scheme 27,25,scheme 27,antibiotics12071220
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5a,MIC,'=',"0,035",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccccc54)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5b,MIC,'=',"0,065",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5c,MIC,'=',"0,067",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5d,MIC,'=',"0,062",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5e,MIC,'=',"0,029",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1)N1CCc2ccccc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5f,MIC,'=',"0,029",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2cnc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5g,MIC,'=',"0,034",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4c5ccccc5CC4C)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5h,MIC,'=',"0,031",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2c3ccccc3CC2C)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5i,MIC,'=',"0,065",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2c3ccccc3CC2C)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5j,MIC,'=',"0,06",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5k,MIC,'=',"0,056",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC1Cc2ccccc2N1C(=O)Cn1cc(Cn2c(-c3ccccn3)nc3ccccc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5l,MIC,'=',"0,028",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2cnc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5m,MIC,'=',"0,031",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1cc2ncn(Cc3cn(CC(=O)N4CCc5ccc([N+](=O)[O-])cc54)nn3)c2cc1C,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5n,MIC,'=',"0,029",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
Cc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5o,MIC,'=',"0,06",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CSc1nc2ccccc2n1Cc1cn(CC(=O)N2CCc3ccc([N+](=O)[O-])cc32)nn1,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5p,MIC,'=',"0,029",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5q,MIC,'=',"0,026",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
O=C(Cn1cc(Cn2c(-c3ccccc3)nc3ccccc32)nn1)N1CCc2ccc([N+](=O)[O-])cc21,10.1007/s11696-022-02436-1,"Synthesis, antimicrobial and α-glucosidase inhibition of new benzimidazole-1,2,3-triazole-indoline derivatives: a combined experimental and computational venture",Springer Science and Business Media LLC,2022,0,5r,MIC,'=',"0,013",µmol/mL,S. aureus,Staphylococcus aureus,11,table 3,,,11,table 3,,,4,scheme 3,5,table 1,s11696-022-02436-1
CC(NC(=O)n1c(NC(=N)N)nc2ccccc21)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,8,MIC,>,1000,µg/mL,S. aureus,,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=O)NC(=N)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,9,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=O)n1c(N)nc2ccccc21)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,13,MIC,'=',500,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@@H](NC(=S)NC(=N)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,10,MIC,>,1000,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=S)NC(=N)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,11,MIC,>,1000,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@@H](NC(=S)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,18,MIC,>,1000,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=O)Nc1[nH]c2ccccc2c1C#N)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,39,MIC,>,1000,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=S)Nc1ccc2[nH]ccc2c1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,20,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
CC(NC(=O)Nc1c[nH]c2ccccc12)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,21,MIC,>,1000,µg/mL,S. aureus,,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=O)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,16,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
C[C@H](NC(=S)Nc1nc2ccccc2[nH]1)c1ccccc1,10.1016/j.molstruc.2021.130566,"Design, synthesis, antimicrobial evaluation, and molecular docking of novel chiral urea/thiourea derivatives bearing indole, benzimidazole, and benzothiazole scaffolds",Elsevier BV,2021,0,17,MIC,'=',250,µg/mL,S. aureus,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,,,j.molstruc.2021.130566
COc1cc(-c2nc3ccccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3a,MIC,'=',"0,135",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Cl)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3b,MIC,'=',"0,252",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Br)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3c,MIC,'=',"0,247",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(C)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3d,MIC,'=',"0,131",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1ccc2nc(-c3cc(OC)c(O)c4c[n+]5c(cc34)-c3cc4c(cc3CC5)OCO4)[nH]c2c1.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3e,MIC,'=',"0,254",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4a,MIC,'=',"0,127",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4b,MIC,'=',"0,121",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4c,MIC,'=',"0,059",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4d,MIC,'=',"0,007",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4e,MIC,'=',"0,218",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4f,MIC,'=',"0,104",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5a,MIC,'=',"0,015",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CCCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5b,MIC,'=',"0,028",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C=CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5c,MIC,'=',"0,031",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C#CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5d,MIC,'=',"0,031",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCO)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6a,MIC,'=',"0,247",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6b,MIC,'=',"0,47",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6c,MIC,'=',"0,218",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7a,MIC,'=',"0,027",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(F)cc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7b,MIC,'=',"0,053",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7c,MIC,'=',"0,003",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7d,MIC,'=',"0,013",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)c(Cl)c2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7e,MIC,'=',"0,025",µmol/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8a,MIC,'=',"0,219",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8b,MIC,'=',"0,213",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
CCN(CC)C(=O)Cn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9c,MIC,'=',"0,218",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N(C(C)C)C(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9b,MIC,'=',"0,208",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)OC(C)(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,10,MIC,'=',"0,218",µmol/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8b,MIC,'=',25,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8c,MIC,'=',25,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8d,MIC,'=',50,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8g,MIC,'=',25,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8h,MIC,'=',"12,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8i,MIC,'=',"12,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8l,MIC,'=',25,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8m,MIC,'=',"12,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8o,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8a,MIC,'=',"3,125",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8e,MIC,'=',"3,125",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8f,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2ccc(Cl)cc2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8j,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8k,MIC,'=',"1,6",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2F)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8n,MIC,'=',"1,6",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8p,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4cccnc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8q,MIC,'=',"3,125",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccccc4Cl)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8r,MIC,'=',"3,125",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(Cc4cccc(Cl)c4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8s,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
Cn1c(-c2cccc(Cl)c2Cl)nc2cc(-c3nc(-c4ccc(S(C)(=O)=O)cc4)no3)ccc21,10.1039/c5ra23282a,Novel benzimidazole–oxadiazole hybrid molecules as promising antimicrobial agents,Royal Society of Chemistry (RSC),2016,0,8t,MIC,'=',25,µg/mL,S. aureus,Staphylococcus aureus,5,table 2,,,5,table 2,,,4,scheme 3,5,table 2,c5ra23282a
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccc4)nc3-c3ccccc3)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28b,MIC,'=',312,µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
Oc1ccccc1-c1nn(-c2ccccc2)cc1-c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28c,MIC,'=',312,µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccc4)nc3-c3ccccc3O)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28d,MIC,'=',"62,5",µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
c1ccc(-c2nn(-c3ccccn3)cc2-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28e,MIC,'=',"62,5",µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccn4)nc3-c3ccccc3)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28f,MIC,'=',"187,5",µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
Oc1ccccc1-c1nn(-c2ccccn2)cc1-c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28g,MIC,'=',"62,5",µg mL-1,S. aureus,Escherichia coli,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=[N+]([O-])c1ccc2[nH]c(-c3cn(-c4ccccn4)nc3-c3ccccc3O)nc2c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,28h,MIC,'=',"62,5",µg mL-1,S. aureus,,7,table 1,,,7,table 1,,,6,scheme 8,6,scheme 8,antibiotics10081002
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,67,MIC,'=',"0,68",µg mL-1,S. aureus,,12,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,12,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,13,scheme 17,,,antibiotics10081002
CCCCn1c(Cc2cc(C)[nH]n2)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,70,MIC,'=',"12,5",µg mL-1,S. aureus,,13,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,13,text,"2. Synthesis, Antimicrobial Activities of Benzimidazole–Pyrazole Compounds. Benzimidazole–Pyrazole Compounds as Potent DNA Gyrase and Topoisomerase IV Inhibitors",2.1. Benzimidazoles Substituted in the “2” Position with Pyrazole Moiety,14,scheme 18,,,antibiotics10081002
Cc1cc(=O)n(Cc2nc3ccccc3[nH]2)[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,83a,MIC,'=',"156,25",µg mL-1,S. aureus,Staphylococcus aureus,16,table 9,,,16,table 9,,,17,scheme 22,17,scheme 22,antibiotics10081002
Cc1cc(=O)n(Cc2nc3ccc([N+](=O)[O-])cc3[nH]2)[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,83b,MIC,'=',2500,µg mL-1,S. aureus,Staphylococcus aureus,16,table 9,,,16,table 9,,,17,scheme 22,17,scheme 22,antibiotics10081002
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',256,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',256,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',32,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',16,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',32,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',256,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3c,MIC,'=',4,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',512,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',256,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',16,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',64,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',128,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',512,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',256,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4d,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',256,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',512,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',512,µg/mL,S. aureus,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',32,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',16,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',64,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',32,µg/mL,S. aureus,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
COc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccccc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6a,MIC,>,"163,2",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(C)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6b,MIC,>,"157,4",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6c,MIC,>,"155,9",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Cl)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6d,MIC,'=',"149,9",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Br)cc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6e,MIC,'=',"67,8",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccccc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6f,MIC,>,"163,2",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(C)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6g,MIC,'=',"19,6",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(F)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6h,MIC,'=',"77,9",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Cl)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6i,MIC,'=',"149,9",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
COc1cccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccc(Br)cc3[N]2)c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6j,MIC,'=',"67,8",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2C2=Nc3ccccc3[N]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6k,MIC,'=',"80,7",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Cc1ccc2nc(-c3sc(N4CCOCC4)nc3-c3ccc(Cl)cc3)[nH]c2c1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6l,MIC,>,"155,7",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Fc1ccc2c(c1)[N]C(c1sc(N3CCOCC3)nc1-c1ccc(Cl)cc1)=N2,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6m,MIC,'=',"77,2",µM,S. aureus,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6n,MIC,>,"148,8",µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
Clc1ccc(-c2nc(N3CCOCC3)sc2-c2nc3ccc(Br)cc3[nH]2)cc1,10.1016/j.bioorg.2023.106538,"Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials",Elsevier BV,2023,0,6o,MIC,>,135,µM,S. aureus,,4,table 2,,,4,table 2,,,3,figure 2,,,j.bioorg.2023.106538
CCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5a,MIC,'=',"9,375",µg/mL,S.aureus,Staphylococcus aureus,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
CCCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5b,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
N#CCn1c(C2CCN(c3cc(C(F)(F)F)cc(-c4ccccc4)n3)CC2)nc2ccccc21,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,5c,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 2,2,scheme 2,1570180811666140725185713
FC(F)(F)c1cc(-c2ccccc2)nc(N2CCC(c3nc4ccccc4[nH]3)CC2)c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4a,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
FC(F)(F)c1cc(-c2ccccc2)nc(N2CCC(c3nc4ccc(Cl)cc4[nH]3)CC2)c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4b,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Fc1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4c,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4d,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
O=C(c1ccccc1)c1ccc2nc(C3CCN(c4cc(C(F)(F)F)cc(-c5ccccc5)n4)CC3)[nH]c2c1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4e,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4ccccc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4f,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4ccc(C(=O)c5ccccc5)cc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4g,MIC,>,150,µg/mL,S.aureus,,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
Cc1cc(C(F)(F)F)cc(N2CCC(c3nc4cc(Cl)ccc4[nH]3)CC2)n1,10.2174/1570180811666140725185713,"Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents",Bentham Science Publishers Ltd.,2014,0,4h,MIC,>,150,µg/mL,S.aureus,Escherichia coli,3,table 1,,,3,table 1,,,2,scheme 1,2,scheme 1,1570180811666140725185713
CNc1nnc(-c2ccc(-c3nc4cc(C)c(C)cc4[nH]3)cc2)s1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5a,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC(C)C)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5b,MIC,'=',"62,5",µg/mL,S. aureus,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NCCCl)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5c,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(Nc5ccccc5Cl)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5d,MIC,'=',"62,5",µg/mL,S. aureus,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC5CCCCC5)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5e,MIC,'=',125,µg/mL,S. aureus,,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Cc1cc2nc(-c3ccc(-c4nnc(NC(C)C)s4)cc3)[nH]c2cc1C,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5f,MIC,'=',125,µg/mL,S. aureus,Staphylococcus aureus,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
CCCNc1nnc(-c2ccc(-c3nc4cc(C)c(C)cc4[nH]3)cc2)s1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5g,MIC,'=',125,µg/mL,S. aureus,Staphylococcus aureus,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
COc1ccc(Nc2nnc(-c3ccc(-c4nc5cc(C)c(C)cc5[nH]4)cc3)s2)cc1,10.1021/acsomega.2c06142,"Synthesis, Molecular Docking, Dynamics, Quantum-Chemical Computation, and Antimicrobial Activity Studies of Some New Benzimidazole–Thiadiazole Hybrids",American Chemical Society (ACS),2022,1,5h,MIC,'=',"15,625",µg/mL,S. aureus,Staphylococcus aureus,5,table 2 (caption),,,5,table 2,,,5,table 2,5,table 2,acsomega.2c06142
Clc1ccc2c(c1)nc(-c1ccc(OCc3ccccc3)cc1)n2C1CCCC1,10.1016/j.bioorg.2019.103252,Promising antibacterial agents against multidrug resistant Staphylococcus aureus,Elsevier BV,2019,0,25,MIC,'=',"3,12",µg/mL,S. aureus,Staphylococcus aureus,3,text,2. Antibacterial agents,2.3. Benzimidazole derivatives,3,text,,,5,figure 7,5,figure 7,j.bioorg.2019.103252
Fc1ccc(-c2cc(-c3nc4ncccc4[nH]3)c3cc(Cl)ccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLV,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)c3cc(Cl)ccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVI,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4ncccc4[nH]3)c3ccccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVII,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Fc1ccc(-c2cc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)c3ccccc3n2)cc1,10.5772/intechopen.108949,Current Development in the Synthesis of Benzimidazole-Quinoline Hybrid Analogues and Their Biological Applications,IntechOpen,2023,1,XLVIII,MIC,'=',"6,25",µg/mL,S. aureus,Staphylococcus aureus,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,text,2. Biological applications of benzimidazole-quinoline hybrids,2.2 Antimicrobial activity,8,figure 17,8,figure 17,intechopen.108949
Cn1c(-c2c(F)cccc2Cl)nc2cc(-c3nc(-c4ccc(Cl)cc4)no3)ccc21,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,15,MIC,'=',"6,25",µg/mL,S. aureus,,4,text,Antibacterial Potential of Novel Benzimidazole–Oxadiazole Hybrid Compounds,,4,text,Antibacterial Potential of Novel Benzimidazole–Oxadiazole Hybrid Compounds,,5,figure 7,,,RJC.2023.1638382
CC1=NN(c2ccc(Cl)cc2)C(=O)C1=NNc1ccc(-c2ccc(C3=Nc4ccccc4[N]3)cc2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,34,MIC,'=',"7,81",µg/mL,S. aureus,Staphylococcus aureus,7,text,Agents,,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,figure 11,,,RJC.2023.1638382
CC1=NN(c2cccc(Cl)c2)C(=O)/C1=N/Nc1ccc(-c2ccc(C3=Nc4ccccc4[N]3)cc2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,35,MIC,'=',"7,81",µg/mL,S. aureus,Staphylococcus aureus,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,text,Novel Benzimidazole- Pyrimidine/Pyrazole/Isoxazole Hybrid Derivatives as Antibacterial Agents,,7,figure 11,,,RJC.2023.1638382
Clc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,47b,MIC,'=',4,µg/mL,S. aureus,Staphylococcus aureus,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,figure 17,,,RJC.2023.1638382
c1ccc(-c2nc(Nc3ccc(-c4nc5ccccc5[nH]4)cc3)c3ccccc3n2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,47c,MIC,'=',4,µg/mL,S. aureus,Staphylococcus aureus,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,figure 17,,,RJC.2023.1638382
Clc1ccc(-c2ccc(-c3nc(Nc4ccc(-c5nc6ccccc6[nH]5)cc4)c4ccccc4n3)cc2)cc1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,47h,MIC,'=',4,µg/mL,S. aureus,Staphylococcus aureus,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,figure 17,,,RJC.2023.1638382
Fc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccc(-c6ccc(Cl)cc6)cc5)nc5ccccc45)cc3)nc2c1,10.31788/RJC.2023.1638382,ANTIBACTERIAL POTENTIAL OF BENZIMIDAZOLE CONTAINING HYBRID DERIVATIVES,Rasayan Journal of Chemistry,2023,1,47i,MIC,'=',4,µg/mL,S. aureus,Staphylococcus aureus,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,text,Antibacterial Activity of New Quinazoline-Benzimidazole Hybrid Derivatives,,10,figure 17,,,RJC.2023.1638382
C[C@H]1COc2c(F)c(F)cc3c(=O)c(-c4nc5ccccc5n4C)cn1c23,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-1,MIC,'=',"1,25",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2c(F)c(F)c(F)c(F)c2-c2nc3ccccc3n2C)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-2,MIC,'=',"1,25",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(F)c(F)c2F)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-3,MIC,'=',5,µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(Cl)cc2Cl)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-4,MIC,'=',5,µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cc(F)c(Cl)c(Cl)c2Cl)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-5,MIC,'=',"1,25",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cn1c(-c2cnccn2)nc2ccccc21,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-6,MIC,'=',5,µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
CCCc1nc2c(C)cc(-c3nc4ccccc4o3)cc2[nH]1,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-7,MIC,'=',"0,625",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cccc(F)c1Cn1cc(-c2nc3ccccc3o2)nn1,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-8,MIC,'=',5,µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1c(F)c(F)c(-c2nc3ccccc3o2)c(-c2nc3ccccc3o2)c1F,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-9,MIC,'=',"2,5",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cc(-c2nc3ccccc3o2)c(Cl)cc1Cl,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-10,MIC,'=',"2,5",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Fc1cc(-c2nc3ccccc3o2)c(Cl)c(Cl)c1Cl,10.1002/jhet.3467,"Design, Synthesis, <i>In Vitro</i> Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives",Wiley,2019,0,BK-11,MIC,'=',"2,5",µg/mL,S. aureus,Escherichia coli,5,table 3,,,5,table 3,,,4,table 2,,,jhet.3467
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccccc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,13,MIC,>,"62,5",µg/mL,S. aureus,,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccccc2C)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,14,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cccc(C)c2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,15,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,16,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccc(Cl)cc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,17,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccccc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,18,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccccc1C(=O)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,19,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1cccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,20,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,21,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccc(Cl)cc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,22,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccccc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,23,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccccc1C(=O)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,24,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1cccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,25,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,26,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccc(Cl)cc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,27,MIC,>,"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cccnc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,28,MIC,'=',"31,25",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2cncc(C)c2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,29,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccc(C)nc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,30,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,31,MIC,'=',"0,98",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1cncc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,32,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(F)cc3)nc3ccccc32)cn1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,33,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1cccnc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,34,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1cncc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)c1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,35,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(C(=O)n2c(-c3cn(-c4ccccc4)nc3-c3ccc(C(F)(F)F)cc3)nc3ccccc32)cn1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,36,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc(-c2nn(-c3ccccc3)cc2-c2nc3ccccc3n2C(=O)c2ccncc2)cc1,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,37,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccncc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,38,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
O=C(c1ccncc1)n1c(-c2cn(-c3ccccc3)nc2-c2ccc(C(F)(F)F)cc2)nc2ccccc21,10.1016/j.ejmech.2019.03.026,"Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination",Elsevier BV,2019,0,39,MIC,'=',"62,5",µg/mL,S. aureus,Staphylococcus aureus,5,table 3,,,5,table 3,,,3,scheme 2,3,scheme 2,j.ejmech.2019.03.026
Cc1ccc2c(c1)n(CC(=O)c1ccccc1)c(=N)n2CC(=O)c1ccccc1,10.1016/j.bmc.2015.08.029,"Synthesis, electronic properties, antioxidant and antibacterial activity of some new benzimidazoles",Elsevier BV,2015,0,10,MIC,'=',"0,5",mg/mL,S. aureus,Staphylococcus aureus,3,table 1,,,3,table 1,,,3,scheme 1,3,scheme 1,j.bmc.2015.08.029
Cc1ccc2c(c1)n(CCCc1ccccc1)c(=N)n2CCCc1ccccc1,10.1016/j.bmc.2015.08.029,"Synthesis, electronic properties, antioxidant and antibacterial activity of some new benzimidazoles",Elsevier BV,2015,0,14,MIC,'=',"0,016",mg/mL,S. aureus,Staphylococcus aureus,3,table 1,,,3,table 1,,,3,scheme 1,3,scheme 1,j.bmc.2015.08.029
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C=O)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,6a,MIC,'=',"11,03",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C=O)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,6b,MIC,'=',"3,19",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5ccccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7a,MIC,'=',"1,15",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5ccccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7h,MIC,'=',"0,32",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1ccc2c(c1)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(Br)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7b,MIC,'=',"0,56",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(Br)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7c,MIC,'=',"4,39",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Cl)ccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7f,MIC,'=',"0,07",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Br)ccc5[N]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7g,MIC,'=',"8,06",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(F)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7k,MIC,'=',"0,63",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc2c(cc1C)N=C(c1cc(Cn3cc(Cn4c(=O)cc(C)c5cc(F)ccc54)nn3)ccc1O)[N]2,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7j,MIC,'=',"2,46",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Br)ccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7n,MIC,'=',"4,47",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(C4=Nc5cc(Cl)ccc5[N]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7m,MIC,'=',"2,43",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5cc(F)ccc5[nH]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7d,MIC,'=',"2,23",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5ccc(C(F)(F)F)cc5[nH]4)c3)nn2)c2ccc(Br)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7e,MIC,'=',"1,03",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1ccc2[nH]c(-c3cc(Cn4cc(Cn5c(=O)cc(C)c6cc(F)ccc65)nn4)ccc3O)nc2c1,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7i,MIC,'=',"10,11",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
Cc1cc(=O)n(Cc2cn(Cc3ccc(O)c(-c4nc5ccc(C(F)(F)F)cc5[nH]4)c3)nn2)c2ccc(F)cc12,10.1016/j.molstruc.2023.135179,"Synthesis, structural characterization and antibacterial activity evaluation of novel quinolone-1,2,3-triazole-benzimidazole hybrids",Elsevier BV,2023,0,7l,MIC,'=',"0,14",µmol/mL,S. aureus (CIP 54127),Staphylococcus aureus,9,table 3,,,9,table 3,,,7,scheme 2,6,table 1,j.molstruc.2023.135179
O=C(O)CC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,4,MIC,'=',"42,33",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,5,MIC,'=',"20,205",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,6,MIC,'=',"148,2",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,7,MIC,'=',"37,05",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,8,MIC,'=',"79,8",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,9,MIC,'=',"38,19",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,10,MIC,'=',"4,57",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,11,MIC,'=',"70,35",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3cc(F)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,12,MIC,'=',"35,17",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,13,MIC,'=',"75,8",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,14,MIC,'=',"36,36",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,15,MIC,'=',"34,9",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,16,MIC,'=',"67,23",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,17,MIC,'=',"33,61",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,18,MIC,'=',"9,18",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,19,MIC,'=',"19,96",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,20,MIC,'=',"33,9",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,21,MIC,'=',"32,69",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,22,MIC,'=',"32,6",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)CC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,23,MIC,'=',"38,42",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)CCC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,24,MIC,'=',"73,67",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)CCCC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,25,MIC,'=',"35,37",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ccc(OC)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,26,MIC,'=',"68,04",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)CCCCC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,27,MIC,'=',"68,04",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,28,MIC,'=',"42,18",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,29,MIC,'=',"20,14",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,30,MIC,'=',"38,54",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COC(=O)CCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,31,MIC,'=',"36,94",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CCCCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,32,MIC,'=',"4,61",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,33,MIC,'=',"38,42",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,34,MIC,'=',"73,3",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,35,MIC,'=',"9,102",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ccc(F)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,36,MIC,'=',"34,78",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,37,MIC,'=',"34,74",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,38,MIC,'=',"4,15",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,39,MIC,'=',"33,75",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,40,MIC,'=',"8,087",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)COCC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,41,MIC,'=',"17,58",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1ccc2nc(-c3ccc(NC(=O)CSCC(=O)O)cc3)[nH]c2c1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,42,MIC,'=',"67,31",µM,MTCC 3160,,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)COCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,43,MIC,'=',"19,15",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
O=C(O)CSCC(=O)Nc1ccc(-c2nc3ncccc3[nH]2)cc1,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus,Elsevier BV,2014,0,44,MIC,'=',"4,55",µM,MTCC 3160,Staphylococcus aureus,5,table 1,,,5,table 1,,,5,table 1,5,table 1,j.bmc.2014.09.008
COc1cc(-c2nc3ccccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3a,MIC,'=',"0,068",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Cl)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3b,MIC,'=',"0,504",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(Br)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3c,MIC,'=',"0,247",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3cc(C)ccc3[nH]2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3d,MIC,'=',"0,016",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1ccc2nc(-c3cc(OC)c(O)c4c[n+]5c(cc34)-c3cc4c(cc3CC5)OCO4)[nH]c2c1.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,3e,MIC,'=',"0,127",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4a,MIC,'=',"0,008",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4b,MIC,'=',"0,015",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4c,MIC,'=',"0,029",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4d,MIC,'=',"0,229",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4e,MIC,'=',"0,055",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
CCCCCCCCCCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,4f,MIC,'=',"0,208",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5a,MIC,'=',"0,03",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC2CCCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5b,MIC,'=',"0,056",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C=CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5c,MIC,'=',"0,498",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
C#CCn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,5d,MIC,'=',"0,25",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCO)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6a,MIC,'=',"0,124",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6b,MIC,'=',"0,235",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CCN2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,6c,MIC,'=',"0,436",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7a,MIC,'=',"0,055",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(F)cc2F)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7b,MIC,'=',"0,007",µmol/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccccc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7c,MIC,'=',"0,214",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2Cl)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7d,MIC,'=',"0,006",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2Cc2ccc(Cl)c(Cl)c2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,7e,MIC,'=',"0,025",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8a,MIC,'=',"0,219",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N2CCOCC2)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,8b,MIC,'=',"0,213",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
CCN(CC)C(=O)Cn1c(-c2cc(OC)c(O)c3c[n+]4c(cc23)-c2cc3c(cc2CC4)OCO3)nc2ccccc21.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9c,MIC,'=',"0,218",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)N(C(C)C)C(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,9b,MIC,'=',"0,208",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
COc1cc(-c2nc3ccccc3n2CC(=O)OC(C)(C)C)c2cc3[n+](cc2c1O)CCc1cc2c(cc1-3)OCO2.[Cl-],10.1021/acs.jafc.1c02545,Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>,American Chemical Society (ACS),2021,0,10,MIC,'=',"0,218",µmol/mL,S. aureus ATCC 29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,acs.jafc.1c02545
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Cl)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,12,MIC,'=',"1,56",µg ml-1,S. aureus ATCC 6538P,Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,13,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Br)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,14,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(C(F)(F)F)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,15,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(Cl)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,16,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccccc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,17,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc([N+](=O)[O-])c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,18,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
Cc1cccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,19,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
COc1ccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,20,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1F,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,21,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cc(Cl)ccc1Cl,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,22,MIC,>,50,µg ml-1,S. aureus ATCC 6538P,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Cl)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,12,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,13,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(Br)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,14,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(C(F)(F)F)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,15,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc(Cl)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,16,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccccc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,17,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cccc([N+](=O)[O-])c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,18,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
Cc1cccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)c1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,19,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
COc1ccc(CO/N=C(/Cn2cnc3ccccc32)c2cc3ccccc3oc2=O)cc1,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,20,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1ccc(F)cc1F,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,21,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
O=c1oc2ccccc2cc1/C(Cn1cnc2ccccc21)=N\OCc1cc(Cl)ccc1Cl,10.1038/ja.2017.70,Coumarin–benzimidazole hybrids as a potent antimicrobial agent: synthesis and biological elevation,Springer Science and Business Media LLC,2017,0,22,MIC,>,50,µg ml-1,Staphylococcus aureus ATCC 9144,,4,table 1 (caption),,,4,table 1,,,3,figure 2,3,figure 2,ja.2017.70
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',32,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',64,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',128,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',64,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3c,MIC,'=',64,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',256,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',128,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',128,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',256,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4d,MIC,'=',32,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',128,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',64,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',128,µg/mL,S. aureus ATCC25923,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',64,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',512,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',64,µg/mL,S. aureus ATCC25923,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
c1nc(N2CCOCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,1,MIC,'=',512,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc2c(c1)ncn2CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2a,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1cc2ncn(CCn3cnc4c(N5CCOCC5)ncnc43)c2cc1C,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2b,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2c,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
FC(F)(F)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2d,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Cc1nc2cc([N+](=O)[O-])ccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2e,MIC,'=',64,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CC(=O)c1nc2ccccc2n1CCn1cnc2c(N3CCOCC3)ncnc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,2f,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3a,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3b,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3c,MIC,'=',512,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3d,MIC,'=',256,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3e,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3f,MIC,'=',512,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
CCCCCCCCCCCCCCCCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3g,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C=CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3h,MIC,'=',128,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
C#CCn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,3i,MIC,'=',256,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4a,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4b,MIC,'=',16,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4c,MIC,'=',32,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Fc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4d,MIC,'=',64,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccccc1Cn1c(Cn2cnc3c(N4CCOCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4e,MIC,'=',128,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1cccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)c1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4f,MIC,'=',256,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
Clc1ccc(Cn2c(Cn3cnc4c(N5CCOCC5)ncnc43)nc3ccccc32)cc1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,4g,MIC,'=',256,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.bmcl.2018.03.046
c1nc(N2CCCCC2)c2[nH]cnc2n1,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5a,MIC,'=',512,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,5b,MIC,'=',512,µg/mL,S. aureus ATCC29213,,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6a,MIC,'=',512,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
CCCCCCn1c(Cn2cnc3c(N4CCCC4)ncnc32)nc2ccccc21,10.1016/j.bmcl.2018.03.046,Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove,Elsevier BV,2018,0,6b,MIC,'=',512,µg/mL,S. aureus ATCC29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.bmcl.2018.03.046
O=C(O)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3a,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCN(CC)c1ccc(C=NNC(=O)c2ccc(-c3nc4ccc(Cl)cc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3b,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CC(C)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3c,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CSc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3d,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(C(F)(F)F)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3e,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(-c2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3f,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCOc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3g,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(OCc2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3h,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
N#Cc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3i,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccccc1C(=O)O)c1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3j,MIC,'=',256,µg/mL,S. aureus isolate (MRSA),Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
C/C(=N\NC(N)=S)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7a,MIC,'=',200,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NCc1ccccc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7b,MIC,'=',125,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC(C)(C)C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7c,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC1CCCCC1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7d,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NC(C)C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7e,MIC,'=',"62,5",µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
COc1ccccc1NC(=S)N/N=C(\C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7f,MIC,'=',250,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(Cl)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7g,MIC,'=',"62,5",µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(F)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7h,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
COc1ccc(NC(=S)N/N=C(\C)c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7i,MIC,'=',250,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccccc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7j,MIC,'=',200,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
CCNC(=S)N/N=C(\C)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7k,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1ccc(Br)cc1)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7l,MIC,'=',200,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)Nc1cccc(Cl)c1Cl)c1nc2ccc([N+](=O)[O-])cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7m,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,9,table 1,,,jhet.4548
C/C(=N\NC(=S)NCc1ccccc1)c1nc2ccc(Br)cc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7n,MIC,'=',100,µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,10,table 1,,,jhet.4548
C/C(=N\NC(=S)NC1CCCCC1)c1nc2cc(Br)ccc2[nH]1,10.1002/jhet.4548,"Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives",Wiley,2022,0,7o,MIC,'=',"62,5",µg/mL,S. aureus MTCC 96,Staphylococcus aureus,11,table 2,,,11,table 2,,,10,table 1,,,jhet.4548
O=C(Cn1c[n+](CC(=O)c2ccc(-c3ccccc3)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,11h,MIC,'=',"0,00001",µg/mL,S. aureus Staphylococcus. aureus ATCC 25923,Staphylococcus aureus,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(CCn1c[n+](CC(=O)c2ccc(-c3ccccc3)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,12h,MIC,'=',"0,0003",µg/mL,S. aureus Staphylococcus. aureus ATCC 25924,Staphylococcus aureus,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(Cn1c[n+](CC(=O)c2ccc(C(F)(F)F)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,11i,MIC,'=',"0,009",µg/mL,S. aureus Staphylococcus. aureus ATCC 25925,Staphylococcus aureus,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
O=C(Cn1c[n+](CC(=O)c2ccc(Br)cc2)c2ccccc21)Nc1cccc2cccnc12.[Br-],10.1038/s41598-022-21435-6,Quinoline–imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity,Springer Science and Business Media LLC,2022,1,11g,MIC,'=',"0,009",µg/mL,S. aureus Staphylococcus. aureus ATCC 25926,Staphylococcus aureus,9,table 6 (caption),,,9,table 6,,,4,figure 3,4,figure 3,s41598-022-21435-6
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(c4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6a,MIC,'=',"2 ± 0,23",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(c4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,6b,MIC,'=',"1 ± 0,12",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13a,MIC,'=',"2 ± 0,23",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13b,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13c,MIC,'=',"2 ± 0,23",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13d,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13e,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13f,MIC,'=',"0,25 ± 0,02",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(F)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13g,MIC,'=',"4 ± 0,58",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Cl)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13h,MIC,'=',"0,5 ± 0,05",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc(Br)cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13i,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccc([N+](=O)[O-])cc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,13j,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4CC)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14a,MIC,'=',"128 ± 68,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14b,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14c,MIC,'=',"512 ± 49,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14d,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14e,MIC,'=',"32 ± 3,46",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14f,MIC,'=',"32 ± 3,46",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14g,MIC,'=',"128 ± 68,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4CC)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14h,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14i,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14j,MIC,'=',"32 ± 3,46",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14k,MIC,'=',"128 ± 68,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14l,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14m,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14n,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14o,MIC,'=',"32 ± 3,46",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCCCCCCCCCCCCCCCCCn1c(CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)nc2ccccc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,14p,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15a,MIC,'=',"8 ± 1,15",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15b,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15c,MIC,'=',"512 ± 49,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15d,MIC,'=',"128 ± 68,65",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15e,MIC,'=',"8 ± 1,15",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15f,MIC,'=',"4 ± 0,58",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15g,MIC,'=',"4 ± 0,58",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15h,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(Cl)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15i,MIC,'=',"8 ± 1,15",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccccc4F)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15j,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4cccc(F)c4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15k,MIC,'=',"256 ± 137,29",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(F)cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15l,MIC,'=',"16 ± 1,73",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc(Cl)cc4Cl)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15m,MIC,'=',"8 ± 1,15",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(Cc4nc5ccccc5n4Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,15n,MIC,'=',"4 ± 0,58",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CCc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16a,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CCc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,16b,MIC,'=',"4 ± 0,58",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",,6,table 1,,,6,table 1,,,4,scheme 3,4,scheme 3,j.ejmech.2016.01.052
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CNc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17a,MIC,'=',"2 ± 0,23",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
O=C(O)c1cn(C2CC2)c2cc(N3CCN(CNc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,17b,MIC,'=',"1 ± 0,12",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
CCn1cc(C(=O)OC)c(=O)c2cc(F)c(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)cc21,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18a,MIC,'=',"64 ± 6,35",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
COC(=O)c1cn(C2CC2)c2cc(N3CCN(C=Nc4nc5ccccc5[nH]4)CC3)c(F)cc2c1=O,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents,Elsevier BV,2016,0,18b,MIC,'=',"32 ± 3,46",µg/mL,"S. aureus, Staphylococcus aureus ATCC25923",Staphylococcus aureus,6,table 1,,,6,table 1,,,5,scheme 4,5,scheme 4,j.ejmech.2016.01.052
N#CC(=NNc1ccc(CS(=O)(=O)Nc2ncccn2)cc1)C1=Nc2ccccc2[N]1,10.1002/jccs.202000418J,Synthesis and in vivo evaluation of novel benzimidazole-sulfonamide hybrids and Lucilia cuprina maggots' excretion/secretion topical gels for wound healing,Wiley,2021,0,6d,MIC,'=',"11,97 ± 0,15",µg/mL,S. aureus (RCMB10010),Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,jccs.202000418J
CN(C)c1ccc(/C=C/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,1,pMIC,'=',"1,63",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
Oc1ccc2ccccc2c1C=Nc1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,2,pMIC,'=',"1,64",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,3,pMIC,'=',"1,65",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
Oc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,4,pMIC,'=',"1,72",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=[N+]([O-])c1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,5,pMIC,'=',"1,67",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,6,pMIC,'=',"1,67",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=[N+]([O-])c1cccc(/C=N/c2nc3ccccc3[nH]2)c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,7,pMIC,'=',"1,67",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
C/C=N/c1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,8,pMIC,'=',"1,89",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3[nH]2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,9,pMIC,'=',"1,7",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=CCCC/C=N/c1nc2ccccc2[nH]1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,10,pMIC,'=',"1,76",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3[nH]2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,11,pMIC,'=',"1,6",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
C/C=N/c1nc2ccccc2n1C(C)=O,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,12,pMIC,'=',"1,19",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,13,pMIC,'=',"1,15",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=CCCC/C=N/c1nc2ccccc2n1C(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,14,pMIC,'=',"1,39",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
CC(=O)n1c(/N=C/CCCC=O)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,15,pMIC,'=',"1,39",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
O=C(c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1)n1c(/N=C/c2ccc(O)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,16,pMIC,'=',"1,16",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)c(OC)c1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,17,pMIC,'=',"1,16",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,18,pMIC,'=',"1,13",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,3,table 1,,,2023.12.si5a.0471
COc1cc(/C=N/c2nc3ccccc3n2C(=O)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c2)cc(OC)c1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,19,pMIC,'=',"1,09",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2cc(OC)c(OC)c(OC)c2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,20,pMIC,'=',"1,36",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2ccc(-c3ccccn3)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,21,pMIC,'=',"1,15",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=C/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,22,pMIC,'=',"1,15",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,23,pMIC,'=',"1,18",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2c(O)ccc3ccccc23)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,24,pMIC,'=',"1,16",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1cccc([N+](=O)[O-])c1)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,25,pMIC,'=',"1,18",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
O=C(c1ccc2ccccc2c1)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,26,pMIC,'=',"1,17",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
COc1ccc(/C=N/c2nc3ccccc3n2C(=O)c2cccc([N+](=O)[O-])c2)cc1OC,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,27,pMIC,'=',"1,16",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,28,pMIC,'=',"1,39",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CCCCCCCCCCCCCCCC(=O)n1c(/N=C/c2ccc(N(C)C)cc2)nc2ccccc21,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,29,pMIC,'=',"1,37",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
CN(C)c1ccc(/C=N/c2nc3ccccc3n2C(=O)c2ccc3ccccc3c2)cc1,10.48047/ecb/2023.12.si5a.0471,"QSAR, MOLECULAR DOCKING, AND ADME STUDIES OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS",Deuton-X Ltd,2023,1,30,pMIC,'=',"1,17",µM,SA,Staphylococcus aureus,4,table 2,,,4,table 2,,,4,table 1,,,2023.12.si5a.0471
Clc1ccc(-c2nc(Nc3ccc(-c4nc5ccccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8h,MIC,'=',4,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Fc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccc(Cl)cc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8i,MIC,'=',4,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Clc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8b,MIC,'=',8,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
c1ccc(-c2nc(Nc3ccc(-c4nc5ccccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8c,MIC,'=',8,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Fc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8d,MIC,'=',4,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
COc1ccc(-c2nc(Nc3ccc(-c4nc5ccc(Cl)cc5[nH]4)cc3)c3ccccc3n2)cc1OC,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8g,MIC,'=',16,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
O=C(Nc1ccc2nc(C(F)(F)F)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10a,MIC,'=',32,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3ccc(Br)cc3F)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10b,MIC,'=',64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
FC(F)(F)c1nc2ccc(Nc3nc(-c4cccs4)nc4ccccc34)cc2[nH]1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,11,MIC,'=',64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,,,j.ejmech.2020.112996
O=[N+]([O-])c1ccc2nc(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)[nH]c2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8a,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Brc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8e,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
COc1ccc(-c2nc(Nc3ccc(-c4nc5ccc([N+](=O)[O-])cc5[nH]4)cc3)c3ccccc3n2)cc1OC,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8f,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Clc1ccc(-c2nc(Nc3ccc(-c4nc5cc(Cl)ccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8j,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3cnc4c(Cl)cccc4c3)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10c,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3ccc4ccccc4c3)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10d,MIC,>,64,µg/mL,S. aureus ATCC 29213,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
Clc1ccc(-c2nc(Nc3ccc(-c4nc5ccccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8h,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Fc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccc(Cl)cc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8i,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Clc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8b,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
c1ccc(-c2nc(Nc3ccc(-c4nc5ccccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8c,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Fc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8d,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
COc1ccc(-c2nc(Nc3ccc(-c4nc5ccc(Cl)cc5[nH]4)cc3)c3ccccc3n2)cc1OC,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8g,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
O=C(Nc1ccc2nc(C(F)(F)F)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10a,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3ccc(Br)cc3F)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10b,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
FC(F)(F)c1nc2ccc(Nc3nc(-c4cccs4)nc4ccccc34)cc2[nH]1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,11,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,,,j.ejmech.2020.112996
O=[N+]([O-])c1ccc2nc(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)[nH]c2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8a,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Brc1ccc2[nH]c(-c3ccc(Nc4nc(-c5ccccc5)nc5ccccc45)cc3)nc2c1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8e,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
COc1ccc(-c2nc(Nc3ccc(-c4nc5ccc([N+](=O)[O-])cc5[nH]4)cc3)c3ccccc3n2)cc1OC,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8f,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
Clc1ccc(-c2nc(Nc3ccc(-c4nc5cc(Cl)ccc5[nH]4)cc3)c3ccccc3n2)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,8j,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3cnc4c(Cl)cccc4c3)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10c,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
O=C(Nc1ccc2nc(-c3ccc4ccccc4c3)[nH]c2c1)c1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis,Elsevier BV,2021,0,10d,MIC,>,64,µg/mL,E. coli ATCC 25922,Staphylococcus aureus,4,table 1,,,4,table 1,,,3,scheme 2,3,scheme 2,j.ejmech.2020.112996
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4f,MIC,'=',512,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4c,MIC,'=',128,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4d,MIC,'=',128,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4[nH]3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4b,MIC,'=',128,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)n1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4a,MIC,'=',64,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5[nH]4)nn3)cc2)c1C,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,4e,MIC,'=',128,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,3,scheme 2,3,scheme 2,s13065-018-0479-1
Cc1cc(C)nc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5n4Cc4cn(-c5ccc(S(=O)(=O)Nc6nc(C)cc(C)n6)cc5)nn4)nn3)cc2)n1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6a,MIC,'=',32,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1ncccn1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5ncccn5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6b,MIC,'=',64,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1ccccn1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5ccccn5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6c,MIC,'=',64,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
O=S(=O)(Nc1nccs1)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)Nc5nccs5)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6d,MIC,'=',64,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
Cc1noc(NS(=O)(=O)c2ccc(-n3cc(CSc4nc5ccccc5n4Cc4cn(-c5ccc(S(=O)(=O)Nc6onc(C)c6C)cc5)nn4)nn3)cc2)c1C,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6e,MIC,'=',64,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
N=C(N)NS(=O)(=O)c1ccc(-n2cc(CSc3nc4ccccc4n3Cc3cn(-c4ccc(S(=O)(=O)NC(=N)N)cc4)nn3)nn2)cc1,10.1186/s13065-018-0479-1,"Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents",Springer Science and Business Media LLC,2018,1,6f,MIC,'=',256,µg/mL,Sa,Staphylococcus aureus,6,table 1,,,6,table 1,,,4,scheme 4,4,scheme 4,s13065-018-0479-1
Cn1c(-c2c(S(=O)(=O)c3ccccc3)nnc3cc(-c4ccc(Cl)cc4)nn23)nc2ccccc21,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,74,MIC,'=',"25,3",µg mL-1,Staphylococcus aureus,Staphylococcus aureus,14,table 6,,,14,table 6,,,14,scheme 19,,,antibiotics10081002
COc1ccc(-c2nc3sc(-c4ccc(C)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5c,MIC,'=',"06 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5d,MIC,'=',"04 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5f,MIC,'=',"03 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccccc4)nn3c2-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5h,MIC,'=',"04 ± 0,2",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccccc5[nH]4)c(-c4ccc(F)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5i,MIC,'=',"14 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccc([N+](=O)[O-])cc5[nH]4)c(-c4ccc(F)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5j,MIC,'=',"04 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5k,MIC,'=',"03 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Fc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5l,MIC,'=',"07 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(F)cc4)nn3c2-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5n,MIC,'=',"05 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
COc1ccc(-c2nc3sc(-c4ccc(F)cc4)nn3c2-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5o,MIC,'=',"04 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5ccccc5[nH]4)c(-c4ccc(Cl)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5p,MIC,'=',"03 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nn3c(-c4nc5cc(Cl)ccc5[nH]4)c(-c4ccc(Cl)cc4)nc3s2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5r,MIC,'=',"05 ± 0,2",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccccc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5u,MIC,'=',"02 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc([N+](=O)[O-])cc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5v,MIC,'=',"03 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc(Cl)cc4[nH]3)c(-c3ccc(F)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5w,MIC,'=',"09 ± 0,4",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccccc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5x,MIC,'=',"04 ± 0,2",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc([N+](=O)[O-])cc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5y,MIC,'=',"09 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1nn2c(-c3nc4ccc(Cl)cc4[nH]3)c(-c3ccc(Cl)cc3)nc2s1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5z,MIC,'=',"03 ± 0,2",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(C)nn3c2-c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5aa,MIC,'=',"05 ± 0,2",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
Cc1ccc(-c2nc3sc(C)nn3c2-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives",Elsevier BV,2015,0,5acc,MIC,'=',"10 ± 0,1",µg/mL,Staphylococcus aureus,Staphylococcus aureus,6,table 3,,,6,table 3,,,3,scheme 1,4,table 1,j.ejmech.2015.03.024
ClN1N=C(c2c(-c3ccccc3)[nH]c3ccccc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31a,MIC,'=',8,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CN1N=C(c2c(-c3ccccc3)[nH]c3ccccc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31b,MIC,'=',64,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
c1ccc(-c2[nH]c3ccccc3c2C2=NNC(c3nc4ccccc4[nH]3)C2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,31c,MIC,'=',512,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
ClN1N=C(c2c(-c3ccccc3)[nH]c3ccc(-c4ccccc4)cc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32a,MIC,'=',16,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CN1N=C(c2c(-c3ccccc3)[nH]c3ccc(-c4ccccc4)cc23)CC1c1nc2ccccc2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32b,MIC,'=',32,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
c1ccc(-c2ccc3[nH]c(-c4ccccc4)c(C4=NNC(c5nc6ccccc6[nH]5)C4)c3c2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,32c,MIC,'=',64,µg mL-1,Staphylococcus aureus (ATCC-29513),,7,table 2 (caption),,,7,table 2,,,6,scheme 9,6,scheme 9,antibiotics10081002
CC(=Nn1c(N=Cc2cccc(Cl)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5h,MIC,'=',25,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2Cl)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5g,MIC,'=',50,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(Cl)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5i,MIC,'=',"62,5",µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(Br)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5r,MIC,'=',25,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5a,MIC,'=',500,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2O)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5b,MIC,'=',500,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(O)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5c,MIC,'=',100,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(O)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5d,MIC,'=',500,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(F)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5e,MIC,'=',100,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(F)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5f,MIC,'=',250,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccccc2C)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5j,MIC,'=',125,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(C)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5k,MIC,'=',100,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2ccc(C)cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5l,MIC,'=',250,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
COc1cccc(C=Nc2c(C#N)c(-c3ccc([N+](=O)[O-])cc3)c(C#N)c(=O)n2N=C(C)c2nc3ccccc3[nH]2)c1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5m,MIC,'=',100,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
COc1ccc(C=Nc2c(C#N)c(-c3ccc([N+](=O)[O-])cc3)c(C#N)c(=O)n2N=C(C)c2nc3ccccc3[nH]2)cc1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5n,MIC,'=',250,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc([N+](=O)[O-])c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5o,MIC,'=',250,µg/mL,Staphylococcus aureus (MTCC-96),Staphylococcus aureus,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
C/C(=N\n1c(/N=C/c2ccc([N+](=O)[O-])cc2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5p,MIC,'=',500,µg/mL,Staphylococcus aureus (MTCC-96),,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
CC(=Nn1c(N=Cc2cccc(Br)c2)c(C#N)c(-c2ccc([N+](=O)[O-])cc2)c(C#N)c1=O)c1nc2ccccc2[nH]1,10.1016/j.ejmech.2014.06.004,"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs",Elsevier BV,2014,0,5q,MIC,'=',"12,5",µg/mL,Staphylococcus aureus (MTCC-96),,4,table 1 (caption),,,4,table 1,,,3,scheme 1,3,scheme 1,j.ejmech.2014.06.004
O=C(O)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3a,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCN(CC)c1ccc(C=NNC(=O)c2ccc(-c3nc4ccc(Cl)cc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3b,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CC(C)c1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3c,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CSc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3d,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(C(F)(F)F)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3e,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(-c2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3f,MIC,'=',128,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CCOc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3g,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccc(OCc2ccccc2)cc1)c1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3h,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
N#Cc1ccc(C=NNC(=O)c2ccc(-c3nc4cc(Cl)ccc4[nH]3)cc2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3i,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
O=C(NN=Cc1ccccc1C(=O)O)c1ccc(-c2nc3ccc(Cl)cc3[nH]2)cc1,10.1016/j.molstruc.2022.133946,"Benzimidazole-hydrazone derivatives: Synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies",Elsevier BV,2022,0,3j,MIC,'=',256,µg/mL,Staphylococcus aureus ATCC 29213,Staphylococcus aureus,2,table 1 (caption),,,2,table 1,,,3,scheme 1,3,scheme 1,j.molstruc.2022.133946
CC1=NNC(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39a,MIC,'=',"62,5",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccccc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39b,MIC,'=',"31,25",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccc(Cl)cc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39c,MIC,'=',"7,81",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2ccc(F)cc2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39d,MIC,'=',"7,81",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
COc1ccc(N2N=C(C)/C(=N/Nc3ccc(-c4nc5ccccc5[nH]4)cc3)C2=O)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39e,MIC,'=',"62,5",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2cccc(Cl)c2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39f,MIC,'=',125,µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(c2cccc(F)c2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39g,MIC,'=',"15,62",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(C(N)=S)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39h,MIC,'=',125,µg mL-1,Staphylococcus aureus ATCC 9144,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
CC1=NN(C2CCC(N=C=O)C2)C(=O)/C1=N\Nc1ccc(-c2nc3ccccc3[nH]2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,39i,MIC,'=',125,µg mL-1,Staphylococcus aureus ATCC 9144,,9,table 3 (caption),,,9,table 3,,,8,scheme 11,8,scheme 11,antibiotics10081002
c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88a,MIC,'=',"31,25",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
COc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88b,MIC,'=',125,µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Cc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88c,MIC,'=',125,µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Nc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88d,MIC,'=',"62,5",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Clc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88e,MIC,'=',"15,62",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Oc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88f,MIC,'=',"62,5",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Fc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88g,MIC,'=',"15,62",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
O=[N+]([O-])c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88h,MIC,'=',"31,25",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
FC(F)(F)c1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88i,MIC,'=',"15,62",µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
C=Cc1ccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)cc1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88j,MIC,'=',"31,25",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
COc1cc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)ccc1O,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88k,MIC,'=',"62,5",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
O=[N+]([O-])c1cccc(C2CC(c3ccc(NCn4cnc5ccccc54)cc3)=NN2c2ccccc2)c1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,88l,MIC,'=',"31,25",µg mL-1,Staphylococcus aureus ATCC 9144,,17,table 10 (caption),,,17,table 10,,,18,scheme 24,18,scheme 24,antibiotics10081002
Cc1cc(C)n(C(=O)Cn2c(C3CC(=O)N(c4ccc(F)cc4)C3)nc3ccccc32)n1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,94b,MIC,'=',250,µg mL-1,Staphylococcus aureus ATCC 9144,Staphylococcus aureus,18,text,2.2. Benzimidazoles Substituted in the Position “1” with Pyrazole Moiety,,18,text,,,19,scheme 26,19,scheme 26,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cccnc3)cc(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98a,MIC,'=',"0,25",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cccnc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98b,MIC,'=',"0,25",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(CN4CCOCC4)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98c,MIC,'=',"0,25",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(CN4CCOCC4)nc3)c(F)c(-n3cc(C)cn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98d,MIC,'=',"0,063",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(C3=CC(C)=C(CN4CCOCC4)C(=O)C3)c(F)c(-n3cc(C)cn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98e,MIC,'=',"0,016",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(C(C)O)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98f,MIC,'=',"0,125",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(C(O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98g,MIC,'=',"0,063",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc([C@H](O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98h,MIC,'=',"0,25",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc([C@@H](O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98i,MIC,'=',"0,063",µg/mL,S. aureus,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cccnc3)cc(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98a,MIC,'=',4,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cccnc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98b,MIC,'=',2,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(CN4CCOCC4)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98c,MIC,'=',1,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(CN4CCOCC4)nc3)c(F)c(-n3cc(C)cn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98d,MIC,'=',"0,5",µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(C3=CC(C)=C(CN4CCOCC4)C(=O)C3)c(F)c(-n3cc(C)cn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98e,MIC,'=',"0,125",µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(C(C)O)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98f,MIC,'=',3,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc(C(O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98g,MIC,'=',2,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc([C@H](O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98h,MIC,'=',4,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3ccc([C@@H](O)CC)nc3)c(F)c(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,98i,MIC,'=',1,µg/mL,S. aureus + 50% human serum,,20,table 11,,,20,table 11,,,19,scheme 27,20,table 11,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cccnc3)cc(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,101,MIC,'=',"0,063",µg/mL,S. aureus,,21,table 12,,,21,table 12,,,21,scheme 28,,,antibiotics10081002
CCNC(=O)Nc1nc2cc(-c3cncnc3)cc(-n3cccn3)c2[nH]1,10.3390/antibiotics10081002,Synthesis of Antimicrobial Benzimidazole–Pyrazole Compounds and Their Biological Activities,MDPI AG,2021,1,102,MIC,'=',"0,031",µg/mL,S. aureus,,21,table 12,,,21,table 12,,,21,scheme 28,,,antibiotics10081002